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2 ABBREVIATIONS 
AA Arachidonic acid 
ACE Angiotensin converting enzyme 
ACh Acetylcholine 
ACS Acute coronary syndrome 
ADP Adenosine diphosphate 
AgI Augmentation index 
ALT Alanine aminotransferase 
AMPK Adenosine monophosphate kinase 
ANOVA Analysis of variance 
ASA Acetylsalicylic acid 
AST Aspartate aminotransferase 
ATP Adenosine triphosphate 
BMI Body mass index 
C1 Large artery compliance 
C2 Peripheral artery compliance 
cAMP Cyclic adenosine monophosphate 
CETP Cholesterol ester transfer protein 
cGMP Cyclic guanosine monophosphate 
CHD Coronary heart disease 
COX Cyclo-oxygenase 
CRP C-reactive protein 
DIGAMI The Diabetes Insulin-Glucose in Acute Myocardial Infarction 
study 
ECG Electrocardiogram 
GGT Gamma glutamyl transferase 
eNOS Endothelial nitric oxide synthase 
FFA Free fatty acids 
FFM Fat free mass 
GP  Glycoprotein  
GTN Glyceryl trinitrate 
HbA1C Glycosylated hemoglobin A1C 
HDL High density lipoprotein 
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iNOS Inducible nitric oxide synthase 
LDL Low density lipoprotein 
L-NMMA NG-monomethyl-L-arginine 
MAP Mean arterial pressure 
MRI Magnetic resonance imaging 
mRNA Messenger ribonucleic acid 
NO Nitric oxide 
OHA Oral hypoglycaemic agent 
PAI-1 Plasminogen activator inhibitor-1 
PCI Percutaneous coronary intervention 
PGI2 Prostacyclin 
PI3-kinase Phosphatidylinositol 3-kinase 
PP Pulse pressure 
PPP Platelet poor plasma 
PRP Platelet rich plasma 
PWV Pulse wave velocity 
RGD Arginyl-glycyl- alpha-aspartyl sequence 
TXA2 Thromboxane 
UKPDS United Kingdom Prospective Diabetes Study 
VCAM-1 Vascular cell adhesion molecyle-1 
VLDL Very low density lipoprotein 
vWF von Willebrand factor 
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3 ABSTRACT 
Background: Obesity and type 2 diabetes are associated with increased arterial stiffness and 
abnormalities in platelet function. In normal subjects, insulin decreases central arterial wave 
reflection and the augmentation index (AgI), a measure of arterial stiffness. This action of insulin 
is impaired in obese, insulin resistant subjects. Insulin also reduces adenosine diphosphate (ADP) 
induced platelet aggregation in vitro, and this action of insulin is impaired in obese and type 2 
diabetic subjects.  
 
Aims: The present studies were undertaken to investigate the following questions: I) Is 
interindividual variation in insulin’s ability to acutely decrease the AgI specific to insulin or can 
similar variation be observed in response to glyceryl trinitrate (GNT)? II) Does insulin resistance 
in type 2 diabetic patients involve a defect in the action of insulin to diminish the AgI and central 
blood pressure? III) Does insulin treatment enhance the action of insulin to acutely lower the AgI 
in type 2 diabetic patients? IV) Is insulin resistance related to the antiaggregating effect of 
acetylsalicylic acid (ASA)? 
 
Subjects: The study populations consisted of seven healthy young men and 20 middle-aged 
subjects (Study I), 16 type 2 diabetic patients and 19 matched normal subjects (Study II), 13 type 2 
diabetic patients before and after six-month insulin therapy (Study III), and 11 healthy obese and 
10 non-obese subjects (Study IV). 
 
Methods: Whole body insulin sensitivity was determined in all studies by euglycemic insulin 
clamp technique. The basal AgI and insulin and GTN induced changes in the AgI were measured 
non-invasively from radial artery using applanation tonometry and pulse wave analysis. Platelet 
aggregation responses to ADP and arachidonic acid (AA) were assessed in platelet-rich plasma 
before and 1 hour after ingestion of 50 mg ASA using optical aggregometry.  
 
Results: Insulin and GTN both decreased the AgI in a dose-dependent manner and the 
haemodynamic effects of insulin and GTN were closely correlated. Type 2 diabetic patients were 
resistant not only to the action of insulin to stimulate glucose uptake, but also to its ability to 
decrease the AgI and central systolic blood pressure. Six-month combination therapy with 
glimepiride and bedtime insulin improved the AgI measured basally and during hyperinsulinemia. 
The effect of ASA to inhibit platelet aggregation induced by AA and ADP was significantly 
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blunted in a group of obese insulin-resistant subjects compared to age- and gender matched 
normal-weight subjects.  
 
Conclusions: These data suggest that the action of insulin on large arteries is not specific to insulin 
and supports the idea that insulin may act in part via the NO pathway. The defects in insulin-
mediated decreases in central blood pressure might predispose insulin resistant subjects to systolic 
hypertension and insulin therapy has beneficial effects on vascular function. The blunted platelet-
inhibitory effect of ASA may contribute to the increased risk of atherothrombosis in insulin-
resistant individuals.  
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4 INTRODUCTION 
Insulin resistance and type 2 diabetes are major causes of morbidity and mortality in the 
industrialized world. It has been estimated that the prevalence of type 2 diabetes will increase from 
the present 160 million to 215 million in 2010.16 Type 2 diabetes increases the risk of 
cardiovascular disease 2 to 4 fold as compared to non-diabetic subjects.168; 197 Of the patients 
diagnosed with myocardial infarction about 20% have previously known type 2 diabetes.234; 349 
The association between insulin resistance and cardiovascular disease cannot be explained by 
classic risk factors such as smoking, cholesterol and hypertension.169 
 
Large arteries serve as the main buffering vessels for the systolic pressure load. Arteries stiffen by 
ageing, which increases pulse pressure.76 After the age of 50-60 years pulse pressure is a better 
predictor of coronary heart disease (CHD) than systolic or diastolic blood pressure.119 
Smoking,228; 246; 399 hypertension,101; 118 hypercholesterolemia.8; 286; 399 and diabetes99; 211; 245; 310  are 
known causes of both CHD and arterial stiffness, but measures of arterial stiffness also predict 
cardiovascular morbidity and mortality independent of classic risk factors.51; 74; 219 When large 
arteries are stiff they have an impaired ability to buffer the systolic pressure load, which leads to 
early return of the reflected pressure wave from the periphery (aortic bifurcation) and  
augmentation of systolic blood pressure at the level of the ascending aorta. Early wave reflection 
increases left ventricular afterload, decreases diastolic blood pressure and thereby decreases 
coronary blood flow.266 
 
With the use of pulse wave analysis, it is possible to non-invasively estimate central aortic blood 
pressure. Stiffening of arteries can be observed before clinical signs of atherosclerosis develop. 
Obese children and young adults have increased arterial stiffness, even in the face of normal 
peripheral blood pressure.354; 394 It has been previously shown that insulin acutely decreases central 
aortic pressure and the augmentation index (AgI),390 which is a measure of arterial stiffness 
derived from pulse wave analysis.258 Insulin induced vasodilatation of peripheral resistance vessels 
is nitric oxide (NO) dependent.314; 333 Insulin resistance can impair the ability of insulin to cause 
vasodilatation.196; 198; 415 It has also been shown previously that the ability of insulin to acutely 
decrease AgI is blunted in obese and type 1 diabetic subjects.11; 390-392 It is unknown whether this 
defect in insulin action is specific to insulin or whether it is also observed in response to other 
agents known to acutely decrease the AgI such as glyceryl trinitrate (GTN).  In the present series 
of studies we used the technique of pulse wave analysis to compare the effects of two 
vasodilatating substances, insulin and NO donor GTN on large arteries. We also investigated 
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whether type 2 diabetic patients have increased arterial stiffness and impaired insulin-induced 
decrease in the AgI. Since insulin therapy is known to increase insulin sensitivity of glucose 
metabolism, we studied if insulin therapy can decrease stiffness and restore insulin’s vasodilatory 
actions back to normal. 
 
Platelets play an important role in atherosclerosis and thrombus formation. Platelets have insulin 
receptors and insulin can inhibit platelet aggregation.106; 357 Platelets from obese subjects and type 
2 diabetic patients are resistant to the ability of insulin to counteract platelet aggregation.145; 359; 388 
ASA is largely used as an anti-platelet drug and recommended for virtually all type 2 diabetic 
patients to prevent cardiovascular events.4 The platelet response to ASA is blunted in a significant 
proportion of ASA users.142; 174; 367 The reason for such ASA resistance is unknown. We therefore 
studied whether obesity and insulin resistance impair the ability of ASA to prevent platelet 
aggregation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10
5 REVIEW OF THE LITERATURE 
5.1 Normal insulin action 
5.1.1 Glucose metabolism 
Insulin is a peptide hormone produced by the β-cells of the islets of Langerhans. Binding of insulin 
to its receptor leads to autophosphorylation of several tyrosine residues.173 This leads to 
phosphorylation of insulin receptor substrate proteins and thereafter activation of several 
intracellular proteins transmitting the signal downstream. Activation of PI3-kinase is an essential 
step for stimulation of glucose transport to the cell.159 
 
The main target organs for insulin action are skeletal muscle, liver and adipose tissue. In the 
skeletal muscle free fatty acids (FFAs) are the main source of energy in the fasting state and under 
these conditions skeletal muscle accounts for only 10 % of whole body glucose uptake.20 Under 
fasting conditions insulin-independent tissues, such as the brain, account for more than half of 
whole body glucose uptake.91 Glucose and amino acids of food stimulate insulin secretion, which 
in turn stimulates glucose utilization in skeletal muscle.177 Under postprandial conditions skeletal 
muscle, brain and liver each utilize approximately one third of whole body glucose uptake.177 
Under intravenously maintained hyperinsulinemic conditions, the proportion of glucose used by 
skeletal muscle accounts for 70-80% of whole body glucose uptake.93; 416 
 
In the liver insulin inhibits endogenous glucose production.208 In the postprandial state insulin 
suppresses glycogenolysis90 and diverts gluconeogenetic flux from glucose release into glycogen 
synthesis.63; 102 At insulin concentrations over 80 mU/l, hepatic glucose production is completely 
suppressed in normal subjects and half maximal suppression is achieved at 17 mU/l.149; 414 Fasting 
blood glucose is mainly determined by endogenous glucose production92 and both suppression of 
endogenous glucose production and peripheral glucose disposal influence blood glucose levels at 
postprandial state.109 
 
5.1.2 Vascular effects of insulin 
Insulin has a vasodilatatory effect on resistance vessels in skeletal muscles.415 This effect is slow 
and in most studies only observed at supraphysiological insulin concentrations.49; 196; 364; 415; 416  
During the first 2 hours of insulin infusion at submaximal, high physiological rate of 1 mU/kg·min, 
forearm blood flow increases by approximately 20%.415 This vasodilatatory effect is trivial when 
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compared to for instance a classic endothelium-dependent vasodilatator such as acetylcholine 
(ACh), which increases blood flow 500% above basal within a minute at a submaximal 
concentration.257   The ability of insulin to induce peripheral vasodilatation can be abolished by 
inhibiting nitric oxide synthase enzyme with L-NMMA.314; 333 Norepinephrine and other 
vasoconstrictors cannot abolish the effect of insulin on peripheral arteries, suggesting that insulin-
induced vasodilatation is endothelium dependent (Fig. 1).314 Vasodilatator action of insulin is 
blunted in subjects with insulin resistance and endothelial dysfunction.334 Insulin-infusion acutely 
potentiates endothelium-dependent vasodilatation294 and long term insulin therapy has been shown 
to improve endothelial function in type 2 diabetic patients.294; 373 
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Figure 1. Endothelium-dependent contracting and relaxing systems are represented in this figure. 
Acetylcholine (ACh) binds to muscarinic receptor (M) and activates nitric oxide (NO) synthesis 
via the L-arginine (Arg) pathway. NO causes relaxation of the smooth muscle cells by increasing 
the synthesis of cyclic guanosine monophosphate (cGMP) from guanosine triphosphate (GTP). 
Glyceryl trinitrate (GTN) is an exogenous NO-donor. The action of insulin on vessels is at least 
partially mediated by endothelium-derived NO. Relaxation of smooth muscle cells is induced by 
NO, endothelium-derived hyperpolarizing factor (EDHF) and prostacyclin (PGI2). Contracting 
factors are endothelin-1 (ET-1), Thromboxane A2 (TX A2) and prostaglandin (PGH2) and 
angiotensin II (ANG II). NG-monomethyl-L-arginine (L-NMMA) competitively blocks endothelial 
nitric oxide synthase (eNOS). O-2 =superoxide, AT1= type 1 angiotensin 2 receptor, ACE= 
angiotensin converting enzyme. 
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Insulin dilatates also large pre-resistance arteries. Unlike at the level of resistance arteries, insulin 
action on large arteries can be demonstrated at physiological insulin concentrations within 30-60 
minutes.25; 199 391-393 Carotid and femoral artery diameters, measured with ultrasound method, have 
been shown to increase during insulin infusion.25; 199 Insulin acutely decreases the AgI, a measure 
of systemic arterial stiffness.258; 391; 392 The ability of insulin to decrease aortic augmentation and 
the AgI is blunted in insulin resistant obese and type 1 diabetic subjects.390; 391 It is unknown 
whether this defect in insulin action is specific to insulin or whether it is also observed in response 
to other agents known to acutely decrease the AgI such as GTN.  
 
5.1.3 Effects of insulin on platelet function 
PKA
Insulin
Insulin receptor
cAMPAC
 
Figure 2. Overview of major platelet reactions and signalling pathways. Receptors are boxed and 
ligands are circled. ADP indicates adenosine diphosphate; AA, arachidonic acid; AC, adenylate 
cyclase; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; COX, 
cyclooxygenase; DAG, diacyl glycerol; GP, glycoprotein; IP3, inositol trisphosphate; PL, 
membrane phospholipids; NO, nitric oxide; NOS, nitric oxide synthase; PLC, phospholipase C; 
PGI2, prostacyclin; IP-receptor, prostacyclin receptor; PAR, proteinase-activated receptor; PKA, 
protein kinase A; PKG, protein kinase G; TXA2, thromboxane A2; TP-receptor, thromboxane 
receptor; and vWF, von Willebrand factor. 110; 162; 358 
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Insulin has both direct and indirect effects on platelets. Platelets have functional insulin receptors 
but the effects of insulin may also be mediated through vascular endothelium or changes in platelet 
agonists in plasma. Insulin receptors on platelets are capable of binding insulin and undergo 
autophosphorylation.106 Insulin counteracts platelet responses to agonists such as ADP, collagen, 
thrombin, arachidonate and platelet activating factor (Fig. 2).357 Insulin inhibits platelet 
aggregation both in vitro303; 357; 359 and in vivo.145; 388 This action of insulin is associated with 
increases in platelet cyclic GMP and AMP and can be overcome by inhibiting nitric oxide (NO) 
synthesis with L-NMMA.358 The PI3-kinase pathway may mediate the insulin-induced NO- 
dependent increase in cyclic nucleotides.303; 420 It has been suggested that insulin attenuates NO 
dependent increase in cyclic nucleotides.303; 420 It has also been suggested that insulin attenuates 
aggregation by inhibiting cAMP suppression through IRS-1 and Gi, the inhibitory G-protein of 
adenylyl cyclase.110 An increase in cAMP and cAMP-dependent protein kinase A interferes with 
the elevation of intracellular calcium, which is a key step in platelet activation.110 In in vitro 
studies, insulin has been shown to dose-dependently inhibit platelet aggregation to ADP in healthy 
subjects and lean type 2 diabetic patients.21; 357 This in vitro effect of insulin has been suggested to 
be impaired in obese subjects and in obese type 2 diabetic patients compared to lean subjects.359 
There is however also conflicting evidence from other studies, which suggest that insulin may 
even enhance platelet aggregation.152 
 
Platelet hyperaggregability could contribute to the increased risk of atherothrombotic vascular 
disease in type 2 diabetes.135; 169 A defect in insulin-induced inhibition of platelet aggregation is 
only one of several platelet abnormalities described in type 2 diabetes and insulin resistance. Other 
abnormalities include increased arachidonic acid metabolism which increases platelet 
thromboxane production in type 2 diabetes and obesity,79 subnormal threshold for platelet 
activation by agonists such as ADP309 and collagen, which release arachidonic acid (AA) from 
membrane phospholipids in type 2 diabetes and insulin resistant subjects,79; 97; 157; 309 increased  
platelet size,317 thrombin generation,24; 69shortened life span in circulation,72 an increase in 
advanced glycosylation end-products in platelets402 and decreased membrane fluidity.401 Vascular 
synthesis of prostacyclin (PGI2) and platelet sensitivity to PGI2 may be decreased in diabetes.10; 136 
The activity of nitric oxide synthase may be decreased in type 1 and 2 diabetes.289; 290 Increased 
PAI-1 release161 and shear-induced adhesion and aggregation to subendothelium188 have been 
described in type 2 diabetes. Increased number or function of platelet adhesion proteins GP IIb/IIIa 
and P-selectin129; 176; 192; 243; 260; 361 have been described in both obesity and type 2 diabetes. 
Calcium concentrations are increased in type 2 diabetes, hypertension and insulin 
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 resistance34; 156; 213; 355; 362 and intracellular magnesium concentrations are decreased in obesity and 
type 2 diabetes.342 In addition increased oxidative stress associated with hyperglycemia405 and 
decreased plasma antioxidant capacity312; 360 may cause platelet hyperaggregability perhaps 
through increased isoprostane formation.80 Increased isoprostane production, which characterizes 
humans with type 2 diabetes and obesity, could activate platelets through thromboxane receptor, 
even when thromboxane synthesis is inhibited by ASA.81 Hyperglycemia as such may be a cause 
of abnormal platelet function129; 176; 405 and treatment of hyperglycemia has been shown to reduce 
ADP induced platelet aggregation and to reduce thromboxane and isoprostane formation in 
 some78; 80 but not all studies.157; 391; 392 Increased microparticle formation has also been described 
in type 2 diabetes. Microparticles are released when platelets become activated and they may also 
enhance thrombus formation.307; 392; 417 
 
5.1.4 FFA and lipid metabolism 
Hypertriglyceridemia, low HDL cholesterol and small dense LDL cholesterol are metabolic 
abnormalities that characterize insulin resistant obese subjects and type 2 diabetic patients.346 In 
adipose tissue insulin inhibits lipolysis and increases re-esterification of intracellular FFAs into 
triglycerides.421 In the liver insulin decreases VLDL production by decreasing availability of FFA 
for VLDL synthesis and by directly decreasing VLDL triglyceride214; 379 and VLDL1 Apo B 
synthesis.214; 236; 237 Insulin also stimulates the removal of VLDL by increasing the activity of 
lipoprotein lipase, the rate-limiting enzyme of intravascular triglyceride hydrolysis.346 
 
An increase in plasma VLDL, especially VLDL 1 concentration is the most important determinant 
of LDL size.244; 346 When fasting serum triglyceride levels are below 1.5 to 1.7 mmol/l, LDL 
particles are typically large and buoyant.271 Cholesterol ester transfer protein (CETP) exchanges 
lipids between triglyceride rich particles (VLDL and chylomicrons) and LDL and HDL, and 
thereby enriches LDL and HDL with triglycerides and depletes them from cholesterol esters.407 
Hepatic lipase hydrolyses triglycerides and phospholipids, which renders LDL and HDL particles 
small and dense.172; 343 The concentration of LDL cholesterol in insulin resistant subjects is usually 
normal, but the clearance rate of the small dense HDL is increased and therefore the HDL 
cholesterol concentration is decreased.293 Small dense LDL is atherogenic because it is easily 
oxidized and binds readily to arterial wall proteoglycans.69 
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5.1.5 Other effects of insulin 
Insulin lowers serum potassium concentrations by stimulating potassium uptake into skeletal 
muscle and the splachnic bed.89 It also inhibits sodium, potassium and phosphate excretion by the 
kidney.88 The hypokalaemic and antinatriuretic effects of insulin are preserved in patients with 
insulin resistance and type 2 diabetes.256; 322 Insulin attenuates agonist-induced intracellular 
calcium increase in skin fiberoblasts, vascular smooth muscle cells and platelets.60; 155; 164 In 
insulin resistant subjects, high uric acid levels and low renal uric acid clearance rates cluster with 
insulin resistance and dyslipidemia.256 Insulin acutely reduces renal uric acid clearance and this 
effect of insulin is preserved in insulin resistant subjects, thus providing a link between insulin 
resistance and hyperuricemia.256; 382 Insulin also stimulates sympathetic nervous system centrally 
and increases plasma norepinephrine concentrations.18 Insulin regulates the autonomic control of 
heart rate, decreasing vagal tone and increasing sympathetic drive. In insulin resistant subjects, 
basal sympathetic tone is increased and the subsequent response to insulin is blunted.38; 380 
 
5.2 Insulin resistance 
5.2.1 Definitions 
Insulin is a polypeptide hormone that has many normal biological actions in different tissues. 
Insulin resistance is a state where the normal insulin action is blunted. Insulin resistance may 
affect insulin action in many tissues such as muscle, liver and adipose tissue.39 In addition, insulin 
has effects in blood vessels, platelets, the kidney, and the autonomic nervous tissue, which at least 
in theory could be affected by insulin resistance. 
 
Insulin resistance may be said to exist whenever normal concentrations of insulin produce a less 
than normal biologic response. Hormone resistant states may be divided into those due to 
decreased sensitivity to a hormone (i.e., a shift in the dose-response curve to the right), those due 
to a decrease in the maximal response to the hormone, and those that are combinations of 
decreased sensitivity and decreased responsiveness.165 The term insulin sensitivity is, however, 
commonly used merely to denote insulin action. 
 
5.2.2 Causes of insulin resistance 
Obesity is perhaps the main cause of insulin resistance. There is an inverse relationship between 
body mass index (BMI) and insulin sensitivity, although insulin sensitivity may vary greatly at any 
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given BMI. Upper-body obesity is more closely associated with insulin resistance than lower-body 
obesity, which is considered a fairly harmless state.120 There are regional differences in adipocyte 
function. The lipolytic hormones (i.e. catecholamines) are more active in visceral than abdominal 
subcutaneous fat.26 The “portal theory” suggests that FFAs from visceral fat are carried to the 
liver, where they induce hepatic insulin resistance.26 This theory has not been directly proven. 
Another correlate of insulin resistance in obesity is the amount of fat that is stored in the liver and 
skeletal muscle. Ectopic fat accumulation in fatless mice models leads to insulin resistance that can 
be corrected with subcutaneous fat transplantation, thus proving that having fat in the wrong place 
indeed causes insulin resistance.124; 337 
 
Other causes of insulin resistance include physical inactivity. Physical training and increased 
muscle mass improve insulin sensitivity. 207; 412 Men with low physical fitness have a 3.7 fold risk 
of type 2 diabetes as compared to those in the high-fitness category, after adjusting for age, 
smoking, alcohol consumption and parental diabetes. Even after eliminating the influences of 
BMI, HDL-cholesterol, triglycerides and hypertension, the low-fitness group still has a 2.6 fold 
risk of diabetes.385 Genetic factors contribute to insulin resistance. In white population the lifetime 
risk for developing type 2 diabetes was 20-40% for the first-degree relatives of type 2 diabetic 
patients but only 6% for age and weight matched subjects with no family history of type 2 
diabetes.410 Chronic hyperglycemia,411 hypoglycemia,31 high FFA concentrations108 and acidosis87 
also decrease insulin sensitivity. Many diseases also impair insulin sensitivity. Among them are 
conditions associated with excessive secretion of insulin’s counter-regulatory hormones such as 
acromegaly,255 Cushing’s disease261 and phaeochromocytoma.46 Hypo- and hyperthyroidism284; 291 
both decrease insulin sensitivity as well as uremia,85 infections,409 growth-hormone deficiency13 
and non-alcoholic fatty liver.311 
 
5.2.3 Insulin resistance and cardiovascular disease 
Coronary heart disease is the major cause of excess mortality in type 2 diabetes. About 70% of 
deaths in type 2 diabetes are caused by CHD. Mortality from cardiovascular disease and the 
incidence of non-fatal coronary heart disease is 2 to 4 times higher in patients with type 2 diabetes 
than in non-diabetic subjects even after adjusting for the classic risk factors135; 168; 287 and the 
difference between diabetic and non-diabetic women may be as high as 8 fold.197 The risk of 
myocardial infarction in type 2 diabetic patients is equally high as in non-diabetic subjects with 
previous myocardial infarction.135 The risk of coronary heart disease is already increased in non-
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diabetic subjects with hyperinsulinemia.288; 386 The prognosis of myocardial infarction is also 
worse in diabetic than in non-diabetic subjects.7 248 
 
5.3 Measurement of arterial stiffness 
5.3.1 Definitions 
Pulse pressure: Difference between systolic and diastolic blood pressure 
Augmentation: The rise in central systolic pressure caused by wave reflection 
Augmentation index: Augmentation divided by aortic pulse pressure 
Pulse wave velocity: The speed of travel of the pulse along an arterial segment 
Stiffness index β: The ratio of natural logarithm (systolic/diastolic pressures) to the relative change 
in vessel diameter, ln(systolic BP/diastolic Bp)/[(systolic diameter-diastolic diameter)/diastolic 
diameter]. 
Compliance:  A measure of the capacity of volume containing structure to accommodate further 
increases in volume (∆volume /∆pressure) 
Distensibility: The relative change in vessel diameter (or area) for given change in pressure, 
∆diameter /(∆pressure⋅diameter). 
Elastic modulus: The pressure change required for (theoretical) 100% stretch from resting 
diameter. Elastic modulus is the inverse of distensibility, (∆pressure⋅diameter)/∆diameter 
 
5.3.2 Pulse pressure 
Pulse pressure is a surrogate marker of arterial stiffness. In the Framingham cohort diastolic blood 
pressure was the best predictor of CHD in patients < 50 years of age whereas in patients 50-59 
years of age systolic and diastolic blood pressure as well as pulse pressure predicted CHD 
comparably. From 60 years on diastolic blood pressure was negatively correlated with CHD risk 
and pulse pressure was superior to systolic blood pressure in predicting CHD.119 In the Systolic 
Hypertension in the Elderly Program (SHEP) both stroke and total mortality were related to pulse 
pressure independent of mean arterial pressure.101 Pulse pressure can be calculated by dividing 
stroke volume by arterial compliance. In the young pulse pressure and systolic blood pressure is 
determined by stroke volume while the increase in pulse pressure with ageing is caused by a 
decrease in arterial compliance.76 The relationship between atherosclerosis and pulse pressure may 
be bi-directional. Not only do ageing and hypertension decrease arterial wall elasticity and 
predispose to CHD, but arteriosclerosis also decreases elasticity and increases pulse pressure.76 
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The rise in pulse pressure is therefore not only a surrogate marker for arterial stiffness but it may 
also be a feature of atherosclerosis. 
 
Cardiac afterload is mainly determined by peak systolic blood pressure.119 In young subjects 
peripheral amplification of systolic blood pressure masks the rise in central systolic blood 
pressure. The diastolic blood pressure measured peripherally reflects the rise in central diastolic 
blood pressure more accurately. Both central and peripheral diastolic and systolic blood pressures 
rise in parallel until diastolic blood pressure begins to decrease after the age of 50-59 
 years.54 258 With age-dependent increase in large artery stiffness, there is a narrowing of 
differences between central and peripheral systolic blood pressures as a result of both diminished 
peripheral amplification and early wave refection (Fig. 3).119 258 
 
Pulse pressure
Brachial blood pressure
Aortic blood pressure
  
 
 
Figure 3. The effect of aging on aortic and brachial systolic and diastolic blood pressures and 
pulse pressure.54  
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5.3.3 Pulse wave velocity 
Pulse wave velocity (PWV), the velocity of arterial wave propagation between two arterial sites, 
can be measured invasively or non-invasively and used as an index of regional vascular stiffness. 
The speed at which the pulse wave travels through an arterial segment increases with increasing 
stiffness.269 Arterial pulse waves can be detected by pressure-sensitive transducers,29 Doppler 
ultrasonography,338 applanation tonometry,395 photopletysmography224 or MRI.254 The time delay 
between the proximal and distal arterial sites can be measured simultaneously or by gating to the 
peak of the R-wave of the ECG. The distance travelled by the pulse is measured over the body 
surface and calculated as distance/time (m/s).269 Pulse wave velocity can be measured between any 
arterial segments, but it is usually used to measure the wave travel between common carotid and 
femoral or carotid and radial arteries. The distance within arterial tree and body surface is to some 
extent dependent on body habitus and with increasing age the abdominal aorta becomes more 
tortuous387 and can cause underestimation of PWV. The advantage or MRI is the accurate 
determination of path length but its use is limited by cost and time. 
 
PWV has been shown to predict all-cause and cardiovascular mortality independent of blood 
pressure in patients with end-stage renal failure219 and cardiovascular events in hypertensive 
patients independent of classic cardiovascular risk factors.51; 206 An increase of 1 m/s in PWV is 
associated with significant increase in mortality.132 Although measurements of PWV are 
considered to have a good repeatability216; 395 the day to day variation in PWV has also been 
reported to be as high as 16%.66 An average PWV increases from 5 to 12 m/s between 20 and 75 
years of age.267 An aortic PWV > 13 m/s is a strong predictor of mortality in hypertension.42 
 
5.3.4  Augmentation index 
The AgI derived from systolic pulse wave analysis can be used as a measure of arterial stiffness. 
AgI is the proportion of central pulse pressure that results from arterial wave reflection (Fig. 4). It 
can be measured invasively or non-invasively from superficial peripheral arteries by using 
applanation tonometry. The measurements can be made from radial, carotid or femoral arteries. 
Central blood pressure and the AgI can be calculated from the aortic pressure waveform derived 
using a generalized transfer function or measured directly from carotid artery.250; 269 It correlates 
with PWV (r=0.29, p<0.005)406 but is actually a composite measure of left ventricular outflow 
(influenced by myocardial damage, gender, heart rate, aortic stenosis), anatomy (gender, height) 
and aortic stiffness (age, blood pressure and presence and severity of cardiovascular disease).183 
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Vasoactive drugs influence the AgI independently of PWV,181 suggesting that the AgI is 
influenced by the intensity of wave reflection, which is determined by the diameter, muscular tone 
and elasticity of small arterioles and arteries.269 
 
The AgI increases with age138; 178 and is higher in patients with type 1 397 and type 2 53 diabetes and 
hypercholesterolemia399 than in controls with similar peripheral blood pressure. The AgI measured 
from radial artery also correlates with carotid artery intima-media thickness in diabetic and non-
diabetic subjects and predicts coronary artery disease independent of other risk factors.295; 384 
Because of peripheral pulse wave amplification in subjects <50 years of age, systolic blood 
pressure and pulse pressure measured in periphery may not accurately reflect blood pressure in 
ascending aorta (Fig. 3). The AgI and aortic blood pressures derived from pulse wave analysis 
might therefore in the future help in differentiating systolic hypertension from pseudohypertension 
in younger subjects.269 So far there is no evidence that the AgI measured from radial artery has 
prognostic value,269 but a high carotid AgI has been shown to be an independent predictor for 
ischemic threshold in patients with coronary heart disease and of all-cause and cardiovascular 
mortality in patients with end-stage renal failure.184; 219 
 
Second systolic pressure peak, reflected wave
First systolic pressure peak
Aortic valve closure
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AgI= 
Augmentation/ 
Pulse pressure
 
 
Figure 4. Aortic pulse waveform from a 50-year-old subject derived from pulse wave analysis. 
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Several studies have shown a strong correlation between invasively measured AgI and the AgI 
measured from the radial artery using a transfer function.61; 170; 281 The use of generalized transfer 
function is possible because wave transmission properties of the upper limb change little with age, 
disease or drug therapy in adults.258 In these studies however, the pulse wave was calibrated 
against intra-aortic blood pressures. The validity of generalized transfer function has been 
questioned in some recent studies. When calibrated against a sphygmomanometer, central blood 
pressures derived from radial measurements are accurate but the AgI does not correlate well with 
the AgI measured invasively147 or from carotid artery.250 Therefore some authors consider direct 
measurement of the carotid artery AgI250; 269 or even AgI measured at radial artery without use of a 
transfer function147 as a preferable method. 
 
5.3.5 Diastolic pulse contour analysis 
The diastolic part of the pulse wave can be recorded by applanation tonometry and calibrated using 
a sphygmomanometer. Information can be received from both large (capacitative, C1) and 
peripheral (C2) artery compliance. Compliance calculated from invasive and non-invasive 
measurements correlate significantly.70 Reduced C2 is considered to be an early sign of impaired 
pulsatile function. C2 is decreased in hypertensive patients,70 type 2 diabetic patients,245 
postmenopausal women with CHD,70 and smokers.246 Longitudinal studies for diastolic pulse 
contour analysis have not been performed.269 There is no significant correlation between 
measurements performed at radial and posterior tibial arteries. Local arterial properties are likely 
to influence measurement of C1 and C2238 and therefore these measures do not necessarily provide 
measures of overall global stiffness. C2 but not C1 correlates negatively with the AgI measured 
from radial artery (r=-0.36, p<0.001), but in the latter study the AgI was considered a better 
measure of arterial stiffness than C1 or C2 because the AgI changed more by nitroglycerin and has 
a simpler computational model. 
 
5.3.6 Vascular ultrasonography 
The change in the diameter of an artery at a given distending pressure provides a measure of 
arterial stiffness.269 Ultrasound and MRI can both be used for measurement of the change in 
diameter. Parameters such as compliance, distensibility, elastic modulus and stiffness index (β) 
can be calculated if pulse pressure is known at the site of the measurement. Usually the brachial 
artery pulse pressure is used for measurements performed at the carotid artery although pulse wave 
amplification influences pulse pressure at brachial site. Mean brachial arterial blood pressure can 
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be combined with applanation tonometry at the site of the carotid artery to measure carotid pulse 
pressure more accurately.269 The measurements can be made at several different sites such as 
brachial, radial and femoral arteries or aorta. Carotid artery stiffness has been shown to predict 
mortality in end-stage renal failure44 and cardiovascular events after renal transplantation.35 
Reduced aortic distensibility has been associated with increased age,327 CHD,329  
hypertension,327; 328 hypercholesterolemia327 and acute smoking.331 Stiffness indices are also 
increased in type 2 diabetic patients. 103; 310 
 
5.3.7 Digital volume pulse 
Digital volume pulse can be measured noninvasively by using photopletysmography. Both digital 
and radial pulse waveforms can be predicted from digital volume pulse through a generalized 
transfer function in healthy subjects, in hypertensives and after GTN.249 Endothelium-dependent 
vasodilatation in type 2 diabetic subjects is blunted when measured with digital volume pulse.67 
The method is inexpensive and easy to use, but further studies are needed to validate this 
method.269 
 
5.4 Arterial stiffness and vascular risk 
5.4.1 Age 
Arteries become less elastic by ageing. This is caused by an increase in arterial wall thickness 
secondary to hyperplasia of the intima and by loss of elastin in the media and its replacement by 
collagen.82 Pulse pressure, a surrogate marker of arterial stiffness, increases with age. In the 
Framingham cohort pulse pressure averaged 42 mmHg before the age of 50 years, 50 mmHg 
between ages of 50 and 59 years and 62 mmHg after the age of 60 years.119 In cross-sectional 
studies age correlates closely with arterial stiffness when measured with any technique such as 
ultrasound,148; 175; 325 MRI with cine velocity mapping,254 PWV32; 264 and the AgI.180; 258  
5.4.2 Height 
Height is inversely related to the risk of cardiovascular disease even after adjusting for known 
CHD risk factors.73; 140; 166; 273; 298 An increased risk of CHD has been associated with short 
stature.298 An increased risk has been observer in both men and women in cross-sectional273 and 
follow-up73; 140; 166; 298 studies. Regarding the reasons underlying this association, short stature has 
been associated with reduced pulmonary function,73 genetic factors,14; 73 poor childhood 
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nutrition273 and small diameter of coronary arteries.112 Short stature and arterial length increases 
the carotid AgI independent of mean arterial pressure.324 Short stature also correlates with carotid 
artery compliance, heart rate and age.324 Increased wave reflection in systole and increased 
ventricular load may therefore increase the risk of CHD in short individuals. 
 
5.4.3 Gender 
Cross-sectional studies. Women have a higher AgI than men in all age groups and the difference 
increases with age.138 In a group of elderly hypertensive patients matched for age, height and mean 
arterial pressure, there was no difference in systolic blood pressure between men and women, but 
diastolic blood pressure was lower and pulse pressure and the AgI higher in women. Women had a 
5% smaller aortic arch and 11% smaller outflow area. Aortic stiffness indices β and Ep were also 
higher in women. There were no differences in heart rate or stroke volume between men and 
women.123; 406 In an urban Chinese population aged 17 to 85 years there was an increase in aortic, 
arm or leg pulse wave velocities with age but there were no gender differences.32 In another study, 
the aortic and carotid artery compliances were greater in young women than men and decreased 
rapidly with age so that after middle-age women had lower compliance than men.203  
 
In a 3-year follow-up study of hypertensive women who went through menopause during the 
follow-up, aortic root compliance decreased significantly faster than in the control groups of 
hypertensive men and premenopausal women.171 Hormone replacement therapy did not, however, 
lower blood pressure or the AgI values in a follow-up study of post-menopausal diabetic women.139 
In women the systolic outflow time was longer and diastole was shorter than in men.123; 138 The 
greater aortic stiffness after menopause and the increase in the AgI may contribute to the greater 
age-associated increase in left ventricular mass and excess symptomatic heart failure in women 
than in men that are not explained by differences in brachial blood pressure.138 240; 320 
 
5.4.4 Heart rate 
An increased heart rate167 and low heart rate variability95; 96; 217 are associated with an increased 
risk of cardiovascular mortality and morbidity in follow-up studies. Increased heart rate in patients 
with type 2 diabetes is associated with impaired autonomic control of heart rate variation.377 In a 
cross-sectional study, an increased heart rate was also associated with features of insulin resistance 
in non-diabetic subjects.272 The AgI correlates inversely and linearly with heart rate. When heart 
rate was increased with a pacemaker by 10-beats/minute, the AgI decreased 5.6%.398 Ejection 
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duration also shortened and peripheral systolic and diastolic blood pressures increased, but central 
systolic blood pressure measured non-invasively from brachial artery remained unchanged.396 The 
AgI decreases because an increase in heart rate decreases the duration of systole and shifts the 
reflected wave to diastole. The lack of rise in central systolic blood pressure is explained by the 
decrease in wave pressure augmentation.396 The dependency of the AgI on heart rate can be 
considered as a limitation of the method.82 PWV has increased with heart rate in some201 but not in 
all406 cross-sectional studies and the results are conflicting also in studies where pacemakers were 
used to regulate heart rate.202; 398; 406 The increace in PWV may be due to the shortened time 
available for recoil, which results in vessel stiffening.202 
 
5.4.5 Obesity and insulin resistance 
An association between arterial stiffness and obesity or components of insulin resistance syndrome 
has been shown in several studies. In the Atherosclerosis Risk in Communities (ARIC) study, 
arterial stiffness measured with the use of ultrasound was positively correlated with the fasting 
insulin concentration in a cohort of 4701 subjects after adjusting for age, smoking and total 
cholesterol.310 Other cross-sectional studies have confirmed an association between arterial 
stiffness and obesity with methods using ultrasound,127; 354; 371 PWV, 226; 339; 394 the AgI 128; 390 and 
by measuring aortic elasticity with MRI.75 There is also an association between measures of 
arterial stiffness and insulin sensitivity measured with the euglycemic clamp technique127; 390 or by 
using fasting serum insulin concentration.195; 226; 339; 371 
 
5.4.6 Type 2 diabetes 
Increased arterial stiffness measured with ultrasound,103; 310 the AgI,53; 247; 295  
PWV,9; 57; 182; 210; 263; 344 diastolic pulse contour analysis,245 and by assessing the ratio of pulse 
pressure to stroke volume99 has been a consistent finding in type 2 diabetes in several cross-
sectional studies. Arterial stiffness in type 2 diabetes has been associated with increased left 
ventricular mass and wall thickness,99 intima-media thickness,263; 295; 344 and cardiovascular and 
all-cause mortality in end-stage renal failure.319 Arterial stiffness in type 2 diabetes has been 
positively correlated with hyperglycemia,143; 247; 295; 310; 369 hyperinsulinemia,143; 310 insulin 
resistance measured by clamp study,103; 368 duration of diabetes, 103; 344; 369 dyslipidemia263; 344 and 
advanced glycosylation end products in tissue specimens.9 
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5.4.7 Hypertension 
Blood pressure is a major risk factor for cerebrovascular events and coronary heart disease.116; 375 
Traditionally blood pressure has been defined as a systolic and diastolic blood pressure. Recent 
studies have suggested that blood pressure should be envisioned as consisting of a static 
component, mean arterial pressure, and a dynamic component, pulse pressure.258 Mean arterial 
pressure, the product of cardiac output multiplied by total peripheral resistance, is the pressure for 
the steady flow of blood to peripheral tissues and organs. Pulse pressure is the consequence of 
intermittent ventricular ejections. Pulse pressure is influenced by several cardiac and vascular 
factors, but it is the role of large conduit arteries, mainly the aorta, to minimize pulsatility.258 In 
addition to the pattern of left ventricular ejection, the determinants of pulse pressure include the 
cushioning capacity of arteries and the timing and intensity of wave reflections.258 The cushioning 
capacity is influenced by arterial stiffness, usually expressed using the terms of compliance and 
distensibility.258 
 
Increased pulse pressure is a predictor of cardiovascular risk in subjects with essential 
hypertension and after myocardial infarction in follow-up studies.101 118; 253 Two haemodynamic 
components of pulse pressure have been shown to independently predict cardiovascular risk: aortic 
stiffness measured from aortic PWV,45; 205 and early return of reflected waves to the heart evaluated 
from the AgI.219 On the other hand acute changes in blood pressure at the time of measurement 
influence measures of arterial stiffness without changing vessel structure.122 PWV has been shown 
to increase faster in hypertensive than normotensive subjects during a six-year follow-up.36 Well-
controlled hypertensive patients had similar increase in PWV as normotensive subjects.36 In the 
latter study increased serum creatinine, uncontrolled hypertension and increased heart rate were 
significantly correlated with the progression of PWV.36 
 
5.4.8 Smoking 
Acute smoking increases blood pressure, heart rate, the AgI and PWV in intervention studies.105; 
228 Smokers have stiffer arteries than non-smokers measured using the AgI,107; 128; 228; 399 PWV,212 
diastolic pulse contour analysis246 and ultrasound105 in cross-sectional studies.191; 215; 330 The 
vascular effects of smoking and hypertension may however be different. Both smoking and 
hypertension are associated with increased vascular stiffness indices and intima-media 
thickness,150 but only hypertension is associated with increased central pulse pressure and lumen-
to-wall ratio of carotid artery.215 
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5.4.9 Hypercholesterolemia 
Children and adolescents with heterozygous familial8; 286; 378 or sporadic153 hypercholesterolemia 
have been found to have stiffer arteries than normocholesterolemic subjects in cross-sectional 
studies. Arterial stiffness is increased in hypercholesterolemia when measured with different 
ultrasound methods.8; 153; 286; 378 In adults the data are more conflicting. The AgI and central pulse 
pressure have been found to be higher in middle-aged, hypercholesterolemic patients than control 
subjects matched for peripheral blood pressure, height, age, smoking, weight and fasting 
glucose.399 In young men oxidized but not total low density lipoprotein concentration was 
associated with increased stiffness measured with ultrasound and MRI.352 In other studies no 
associations were found between LDL or HDL cholesterol and arterial stiffness.11; 305 
 
5.4.10 Statins 
Despite conflicting data in cross-sectional studies regarding the association of 
hypercholesterolemia and stiffness, statins have consistently been found to decrease arterial 
stiffness in non-diabetic111; 189; 323; 353  and type 2 diabetic patients154 in treatment studies. Statin 
treatment has not improved pulse wave velocity292 or arterial distensibility and compliance190 in 
short-term studies in contrast to studies where treatment has lasted longer.111; 154; 189; 323; 353   This 
suggests that statins may induce structural changes in the vessel wall.269 
 
5.4.11 Antihypertensive drugs 
The effect of antihypertensive drugs on arterial stiffness needs to be differentiated from that on 
blood pressure. GTN, at low doses, decreases the AgI, central systolic blood pressure and pulse 
pressure, with little effect on peripheral vascular resistance, peripheral blood pressure or PWV.179; 
404 In larger doses nitrates lower peripheral systolic blood pressure effectively, but the blood 
pressure returns to baseline within a week of continuous nitrate treatment.276 In the V-HeFT I and 
II studies (Veterans affairs vasodilator-heart failure trials) the combination of hydralazine and 
isosorbide dinitrate had a beneficial effect on the prognosis and symptoms of heart failure. 
Enalapril, however, had a more favourable effect on 2-year survival than the combination of 
hydralazine and isosorbide dinitrate.58 Nitrates might have clinical use in the treatment of systolic 
hypertension if the problem with nitrate tolerance could be solved.  
 
In treatment studies ACE inhibitors,30; 62; 77; 132; 222 angiotensin II inhibitors28; 187 and calcium 
channel blockers133 appear to have beneficial effects on arterial stiffness. Omepatrilat, an agent 
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that inhibits both angiotensin converting enzyme and neutral endopeptidase has also been shown to 
decrease the AgI242; 252 and carotid-femoral PWV.252 In comparative follow-up studies angiotensin 
converting enzyme inhibitors have been shown to reduce PWV similarly221 or more318 than 
calcium channel blockers. ACE inhibitors,30; 62; 77 angiotensin II receptor187 and calcium channel 
blockers133 reduce PWV133 and the AgI62  more than diuretics and beta-receptor blocking  
agents.30; 77; 133; 187 
 
5.4.12 Arterial stiffness as a predictor of vascular disease 
In follow-up studies pulse pressure has been shown to predict cardiovascular disease independent 
of mean arterial pressure.37; 101; 117; 227 This has also been shown in type 2 diabetic patients.68 In the 
Framingham cohort pulse pressure was the best predictor in subjects over 60 years suggesting that 
age-related stiffening of arteries is an important risk factor for coronary heart disease.119 The 
relation of pulse pressure and mean arterial pressure may be different in cerebrovascular disease. 
In the Progetto Ipertensione Umbria Monitoraggio Ambulatoriale (PIUMA) study of 2311 
hypertensive subjects, pulse pressure was an independent predictor of cardiac events, while mean 
arterial but not pulse pressure predicted cerebrovascular events.375 
 
Recently the association between stiffness and cardiovascular disease has also been studied using 
direct measures of arterial stiffness. In cross-sectional studies PWV correlated with cardiovascular 
risk factors such as age, gender, systolic blood pressure, diabetes, heart rate and apolipoprotein 
B,15; 43 carotid plaques and intima-media thickness.422 The AgI derived from non-invasive radial 
artery tonometry predicts the presence and severity of coronary artery lesions independent of 
smoking, total and LDL cholesterol, age, hypertension and diabetes.384 Increased AgI is associated 
with the cardiovascular risk scores ESC (The European society of cardiology), SMART (The 
second manifestations of arterial disease) and EPOZ (The epidemiological prevention study of 
Zoetermeer).262 Increased AgI is also associated with cardiovascular risk factors such as age, blood 
pressure, smoking, cholesterol, body mass index, height, heart rate and gender262 and with left 
ventricular mass and carotid wall thickness.306 Both the AgI and PWV predicted ischemic 
thresholds in patients with coronary heart disease,184 and the AgI measured invasively from the 
ascending aorta with a fluid-filled system is associated with angiographic changes in coronary 
arteries.137 In diastolic pulse contour analysis, especially peripheral arterial compliance (C2) 
correlated with the extent of angiographic changes in coronary arteries as well as various risk 
factors (cholesterol, blood pressure, age and gender).340 In over 3000 elderly subjects of the 
Rotterdam study, aortic stiffness measured by carotid artery distensibility and carotid-femoral 
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PWV measured by ultrasonography were associated with severity of carotid and aortic 
atherosclerotic plaques and the presence of peripheral arterial disease.370 
 
In follow-up studies PWV has predicted cardiovascular and all cause mortality independent of 
other risk factors (age, pre-existing cardiovascular disease, blood pressure, anaemia and left 
ventricular hypertrophy) in end-stage renal disease.45; 220; 319 In end-stage renal disease, the AgI has 
been shown to be even better predictor of overall and cardiovascular mortality than PWV. In the 
latter study every 10 % increase in the AgI increased the risk of cardiovascular death 1.5 fold.219 
After renal transplantation carotid artery distensibility has predicted occurrence of cardiovascular 
disease independent of sex, age, smoking habits, blood pressure, heart rate, serum creatinine, 
cholesterol and haemoglobin levels.35 In hypertensive patients without pre-existing cardiovascular 
disease, PWV has been found to predict coronary events independent of Framingham score or 
classic risk factors51 and cardiovascular, stroke and all-cause mortality independent of previous 
cardiovascular disease, age or diabetes.205; 206 PWV has also been shown to be an independent 
predictor of cardiovascular and all-cause mortality in both diabetic and control subjects.74 
 
5.4.13 Acute regulation of the augmentation index 
In 1879 Murrel showed that GTN acutely decreases the second pressure peak of the pulse wave 
(the AgI) and suggested that this might be the mechanism by which GTN relieves symptoms of 
CHD.265 Since then, relatively few studies have tried to identify factors, which acutely influence 
the AgI.  
 
Nitric oxide is synthesized from L-arginine in endothelial cells, when muscarinic receptors are 
stimulated by acetylcholine (Fig. 1).274 The reaction is catalyzed by nitric oxide synthase (NOS) 
and can be specifically and competitively blocked by L-NMMA.296 Several isoforms of NOS have 
been identified, but only two have been found in the endothelium; inducible NOS (iNOS) and 
endothelial NOS (eNOS).241 eNOS is stimulated by agonists such as ACh, bradykinin, substance 
P, thrombin and ADP.23 The iNOS enzyme is activated in cells by inflammation.372 Nitric oxide, 
released from endothelial cells, binds to guanylate cyclase and increases the concentration of 
intracellular cGMP in the smooth muscle cells, which causes their relaxation and vasodilatation.27 
GTN is a NO donor that causes endothelium independent relaxation of vascular smooth muscle 
cells (Fig. 1).48 
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As discussed above, it has been recently shown that insulin, at physiological doses acutely 
decreases the AgI (Fig. 5)391-393 and that action of insulin is blunted in insulin resistant subjects.390-
392 The mechanism underlying this effect is, however, unknown. Theoretically this effect could be 
endothelium dependent or –independent. The blunting of insulin action could be either specific to 
insulin or a consequence of e.g. impaired vasorelaxation of vascular smooth muscle cells to agents 
such as GTN. 
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Figure 5. Examples of the effect of insulin on radial and aortic pressure waveforms in nonobese 
and obese subjects at various time points of insulin infusion, as measured using applanation 
tonometry and pulse wave analysis.392 
 
 
Low doses of GTN decrease the AgI and central systolic blood pressure by decreasing the amplitude 
of the reflected wave without changing heart rate and brachial artery blood pressure or peripheral 
artery resistance. This effect of GTN occurs in the absence of changes in aortic compliance or pulse 
wave velocity, and reflects vasorelaxation of vascular smooth muscle in pre-resistance 
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 arteries.113; 179; 404 At intermediate doses GTN induces also venous dilatation and large doses cause 
arteriolar vasodilatation.160  
 
5.5 Platelet function 
5.5.1 Normal platelet function 
Platelets play an important role in thrombosis and haemostasis. Platelets start thrombus formation 
by adhesion to damaged endothelium through von Willebrand factor (vWF) and glycoproteins 
(GP) Ib and IIb/IIIa, and to collagen through GP Ia/IIa.321 Aggregation with other platelets is 
mediated by platelet membrane receptor GP IIb/IIIa through vWF and fibrinogen/fibrin. Platelets 
activate the coagulation cascade and secrete vasoactive substances such as serotonin and 
thromboxane A2 that cause vasoconstriction. In addition platelets have receptors to soluble 
agonists such as thrombin, ADP, adrenalin, platelet activating factor, serotonin and thromboxane 
A2, which enhance platelet aggregation by activating GP IIb/IIIa (Fig. 2). To prevent uncontrolled 
thrombus formation antiaggregatory mechanisms need to be present. The most important ones are 
NO, PGI2 and ecto-ADPase secreted by the endothelial cells.204 NO is synthesized also in platelets 
and NO production can be stimulated by insulin and β-adrenoreceptors.21; 289; 358 Platelets have 
both eNOS and iNOS enzymes, but iNOS is only present in small quantities.383 NO produced from 
L-arginine by NOS activates guanylate cyclase enzyme. The increase in cGMP and cAMP 
concentrations in platelets leads to decrease in calcium fluxes and inhibition of aggregation.356  
 
5.5.2 Nitrates and platelets 
Direct NO donors nitroglycerin and sodium nitroprusside decrease platelet aggregation. 300 µg 
GTN sublingually decreases ADP induced aggregation significantly. In vitro the concentrations of 
GTN required to inhibit aggregation are larger than the concentrations used in nitrate therapy.65 
The inhibition of ADP induced aggregation by GTN in vitro is impaired in obesity, obese type 2 
diabetic patients and in patients with stable angina pectoris.21; 64 Both decreased activity of nitric 
oxide synthase 289; 290 and decreased action of NO on guanylate cyclase22 have been described in 
type 2 diabetes. 
 
5.5.3 ASA  
ASA is the recommended first choice for antiplatelet therapy for primary and secondary 
prevention of vascular disease in diabetic patients. ASA at doses exceeding 30 mg inhibits platelet 
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function by permanent acetylation of platelet cyclo-oxygenase (COX-1) at the functionally 
important amino acid serine 529. This prevents the access of AA to the catalytic site of COX-1 at 
tyrosine 385 and irreversibly inhibits platelet-dependent thromboxane formation (Fig. 6).315 This 
occurs in the portal circulation, which is why 95 % of platelet COX-1 is inhibited although very 
little drug is detected systemically and why blood levels of ASA do not correlate with its 
antiplatelet effect.283 The recommended dose of ASA based on large primary and secondary 
prevention trials is 75-325 mg/day.4; 282 Therapeutic benefit has been demonstrated with doses 
ranging from 30 to 1500 mg/day.33 Higher doses may cause more bleeding and gastrointestinal 
side effects and at doses large than 325 mg/day ASA may have a paradoxical effect, because it 
also inhibits prostacyclin synthesis in endothelial cells, which might favour thrombus 
 formation.2; 33; 351 ASA is 170-fold more potent in inhibiting COX-1 than COX-2 enzyme. COX-1 
is a constitutive enzyme while COX-2 is induced in cells in response to inflammation.194 
Theoretically it is possible that induction of COX-2 in the endothelial cells might impair the action 
of ASA on platelets. Normally ASA inhibits COX-1 in endothelial cells when platelets adhere to 
endothelium, but if COX-2 is induced, retrograde transfer of prostaglandin precursors from 
endothelial cells to platelets may occur.315 
 
5.5.4 Other antiplatelet agents 
ADP receptor inhibitors clopidogrel and ticlodipine are thienopyridines. They block ADP 
receptors on platelets and subsequently decrease activation of GP IIb/IIIa (Fig. 7). In comparison 
to ticlodipine clopidogrel has lower toxicity, lower rate of neutropenia and thrombocytopenia and 
when a loading dose is used, faster inhibition of aggregation.348 In Clopidogrel versus Aspirin in 
Patients at Risk of Ischemic Events study (CAPRIE) approximately 20% of patients had diabetes. 
Clopidogrel 75 mg was 19.2% more effective than ASA 325 mg in preventing myocardial 
infarction.3 There was also a significant risk reduction in the diabetic subgroup.40 In Clopidogrel in 
Unstable Angina to Prevent Recurrent Events study (CURE) clopidogrel and ASA in combination 
was 20% more effective than ASA alone to prevent composite end-point of MI, stroke and CV 
death. In subgroup analysis of diabetic patients (22 % of patients had diabetes), there was a trend 
favouring the use of clopidogrel, but the difference was not statistically significant. 419 Clopidogrel 
is now recommended for treatment of unstable angina pectoris and non-Q myocardial infarction, 
after percutaneous coronary intervention (PCI) and for those intolerant to ASA.52; 71 
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ASA
 
 
 
Dipyridamole is a drug with vasodilator and antiplatelet properties. It inhibits phosphodiesterase 
and increases cAMP concentration in platelets (Fig. 7). Other mechanisms of action have also 
been suggested. It has been proved beneficial in prevention of stroke alone and in combination 
with ASA.280 
 
GP IIb/IIIa receptor antagonists are a group of intravenous drugs for short-term use for patients 
undergoing PCI or in acute coronary syndrome (ACS). In case of vascular injury, platelet adhesion 
to damaged endothelium starts clot formation. GP IIb/IIIa receptors participate in platelet adhesion 
to vascular wall collagen through von Willebrand factor.121 Binding of vWF and fibrinogen to GP 
IIb/IIIa is mediated by the RGD sequence. GP IIb/IIIa is also the final step for all pathways of 
platelet activation (Fig. 7). When any agonist activates a platelet, GP IIb/IIIa goes through a 
change in conformation. GP IIb/IIIa then binds to vWF, and vWF mediates binding to other 
platelets and causes platelet aggregation. The change in conformation also increases fibrinogen 
binding and coagulation.285; 316 
Figure 6. The production of prostaglandins from arachidonic acid and their physiological effects.
HPETE indicates hydroperoxyeicosatetraenoic acid; COX, cyclo-oxygenase; HOX,
hydroperoxidase; PG, prostaglandin; Plt, platelet; and RBF, renal blood flow.33 
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GP IIb/IIIa inhibitors that are in clinical use in Finland are abciximab, Fab-fragment of a 
monoclonal antibody against GP IIb/IIIa receptor, and competitive inhibitors tirofiban and 
epitifibatide that mimic RGD. GP IIb/IIIa inhibitors should always be used in combination with 
aspirin and/or thienopyridines that reduce the number of activated GP IIb/IIIa receptors.316 A 
meta-analysis of six trials of intravenous GP IIb/IIIa receptor antagonists in ACS included 6458 
diabetic patients and more than 23072 other patients. In this meta-analysis 30-day mortality was 
reduced from 4 to 1.2 % in diabetic patients. Non-diabetic patients had no survival benefit.300 In 
addition in another meta-analysis of Abciximab use in PCI studies, either with elective or unstable 
angina patients, 1462 diabetic and 5072 non-diabetic patients were analysed. Use of abciximab 
reduced mortality in diabetic patients significantly from 4.5% to 2.5 %. In non-diabetic patients the 
reduction was statistically non-significant. 41 Trials with oral GP IIb/IIIa agonists have not shown 
benefit in any patient group, but they have increased bleeding complications.348 
 
 
 
 
Figure 7. Antiplatelet agents and their mechanisms of action.71 
 
 
5.5.5 ASA resistance 
Since 1997, the American Diabetes Association has recommended ASA for all adults with 
diabetes who have cardiovascular disease or its risk factors.4 The term ’ASA resistance’ has been 
used in several contexts to describe either individuals who experience vascular events despite 
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using ASA,297 or who fail to prolong bleeding time,174 or produce appropriate responses to platelet 
inhibition tests17; 131; 301  and to inhibit aggregation responses to various agonists.134; 142; 367 At the 
moment there are no uniform definition or diagnostic criteria for ASA resistance.151 The causes of 
interindividual variation in ASA responsiveness are poorly understood and could involve in 
clinical trials factors such as non-compliance or drug-interactions.297 Use of non-steroidal anti-
inflammatory drugs (NSAID) may be one cause of ASA resistance. Unlike ASA, NSAIDs are 
reversible inhibitors of COX. They impede the access of ASA to its target in COX-1 enzyme, but 
don’t inhibit COX-1 enzyme permanently. They may prevent cardiovascular events when used 
alone but weaken the cardioprotective effect of ASA when used simultaneously with ASA. 
Ibuprofein interferes with ASA action more than diclofenac and COX-2 inhibitors.114  
 
The antiplatelet effect of a fixed dose of ASA is known not to be constant in all subjects over 
time.142 In the Primary Prevention Project ASA 100 mg/day was given to 4784 subjects with one 
or more cardiovascular risk factors. 1031 subjects had diabetes. Diabetic patients were more obese 
than the non-diabetic subjects, BMI 29 vs 27.3 kg/m2 respectively. While ASA reduced vascular 
events by 41% in non-diabetic subjects, the risk reduction was non-significant (10%) in the 
diabetic patients.308 In a meta-analysis serious vascular events in diabetic subgroup were found to 
be reduced only by 7%, while the risk reduction was about 25% in the whole study population.6 
The reason for the blunted effect of ASA in diabetic patients is unclear. Any of the previously 
mentioned defects in platelet function might be involved. Isoprostanes for instance could activate 
thromboxane receptors despite inhibition of thromboxane production by ASA.59; 80 High 
circulating levels of P-selectin have been associated with ASA resistance.301 Given that insulin 
normally counteracts agonist-stimulated platelet aggregation357 and inhibits platelet recruitment to 
collagen in a whole blood perfusion system,388 it is possible that insulin resistance may impair the 
ability of ASA to inhibit platelet aggregation.21; 359 It is however unclear whether insulin resistant 
obese subjects are also resistant to the antiplatelet effect of ASA.  
´ 
5.6 Insulin and sulphonylurea treatment 
5.6.1 Insulin treatment 
Insulin treatment in type 2 diabetes is mainly targeted to treat chronic hyperglycemia when OHA 
have failed, but it also has other metabolic effects. Insulin therapy improves whole body glucose 
disposal by decreasing hepatic glucose output and enhancing peripheral glucose uptake.144 Insulin 
treatment decreases FFA levels by inhibiting lipolysis and stimulating FFA re-esterification in the 
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adipose tissue.200; 421 Insulin stimulates lipoprotein lipase on the surface of endothelial cells to 
hydrolyse triglyceride-rich lipoproteins.346 Intensive insulin treatment also reduces total serum 
triglyceride, VLDL triglyceride, total cholesterol phospholipids, LDL, apolipoprotein B and HDL3 
subfractions and increases HDL2 subfraction.345  
 
Insulin may have some effects on components of coagulation and fibrinolysis. Increased 
concentrations of PAI-1, vWF and fibrinogen are associated with insulin resistance and type 2 
diabetes.104; 129; 161; 209; 239; 251 Insulin has in most158; 223; 275 but not all381 studies decreased PAI-1 
activity in type 2 diabetic patients. In the study of Yudkin et al CRP decreased with 16-week 
insulin treatment, but parameters of endothelial function and cytokines (vWF, cellular fibronectin, 
thrombomodulin, tissue plasminogen activator antigen, tumor necrosis factor-α, interleukin-6, 
fibrinogen) did not change.418 In Rotterdam study plasma fibrinogen was higher in insulin treated 
type 2 patients than those treated with oral hypoglycaemic agents or diet only, but this was 
considered to reflect poor metabolic control in insulin treated subjects.251 Markers of endothelial 
activation E-selectin and VCAM are increased in type 2 diabetes.12; 55; 260 E-selectin304 and VCAM 
concentration have decreased in some12 but not in all studies with insulin treatment.418 
 
Insulin treatment causes weight gain. With poor glycemic control, people usually lose weight. 
When blood glucose is lowered (with insulin or sulphonylurea) below level of 10-12 mmol/l, 
glucosuria discontinues and this leads to weight gain if eating and exercise habits stay unchanged. 
In average a 1% unit improvement in HbA1C causes 2 kg increase in weight.230  
 
Microalbuminuria is a strong predictor of cardiovascular morbidity and mortality. In addition to 
progression of renal failure, microalbuminuria has been related to increased transcapillary albumin 
leakage, suggesting that microalbuminuria represents a surrogate measure of endothelial 
dysfunction.332 Presence of microalbuminuria increases mortality 2 fold in both type 2 diabetic and 
non-diabetic subjects.100; 126 Insulin or any effective treatment of hyperglycemia decreases urinary 
albumin excretion rate and prevents progression of diabetic nephropathy.5; 268 
 
In DIGAMI I study insulin-glucose infusion was started immediately after myocardial infarction 
and it was followed by long-term subcutaneous insulin treatment. In this study, in patients without 
prior insulin therapy, one-year mortality was reduced by 52% when compared to conventionally 
treated patients.235 At supraphysiological doses insulin has a sluggish vasodilatatory effect in 
peripheral resistance arteries.415 Insulin therapy improves endothelial function in type 2 diabetic 
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patients,294; 373 but insulin therapy has not been shown to decrease blood pressure in type 2 diabetes 
except in one study where insulin pump but not injected insulin decreased blood pressure.313 
Insulin, on the other hand, has been shown to acutely decrease the AgI at physiological doses. In 
these studies, there were no changes in brachial or aortic blood pressures during the time period 
when the changes in the AgI occurred. The subjects were in average 25-28 years old and the first 
systolic peak determined their aortic systolic blood pressure.391-393  
 
5.6.2 Sulphonylureas 
Improving glycemic control with strategies including metformin and sulphonylureas has been 
shown to reduce both macro- and microvascular complications in the UKPDS study.363 The effect 
of HbA1c is much greater for retinopathy than for myocardial infarction.186; 336; 363 A 1% unit 
reduction in HbA1c caused 14% reduction in myocardial infarction.336 Lowering of blood glucose 
with oral sulphonylureas or metformin will also secondarily cause small decrease in plasma 
triglycerides and LDL cholesterol.86; 347  
 
Sulphonylureas stimulate insulin production in pancreatic β-cells by closing the ATP dependent 
K+-channels (K-ATP).232 Glibenclamide, glipizide and glimepiride are the most frequently used 
sulphonylureas in Finland. Glimepiride is long acting 3rd generation sulphonylurea, which can be 
taken once per day and has less hypoglycaemic side effect than older sulphonylureas.302 
Sulphonylureas not only block K-ATP channels in pancreatic β-cells, but also in heart and 
vessels.130 They may interfere with vasodilatation and prevent ischemic preconditioning.130; 270 
Glimepiride is a weaker inhibitor of cardiac K-ATP channels than glibenclamide and might 
therefore be less harmful for ischemic preconditioning.125 FFAs can activate K-ATP channels.115 
High FFA concentrations interfere with both NO-dependent and independent vasodilatation, yet 
when infused acutely FFAs mediate vasodilatation.84 FFA mediated vasodilatation may therefore 
involve K-ATP channels. 
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6 AIMS OF THE STUDIES 
 
The present studies were undertaken to answer the following questions: 
 
1) Is interindividual variation in insulin’s ability to acutely decrease the AgI specific to insulin 
or can similar variation be observed in the response of the AgI to GNT? (Study I) 
 
2) Are large arteries of type 2 diabetic patients more resistant to the ability of insulin to acutely 
decrease the AgI than arteries of non-diabetic subjects? (Study II) 
 
3) Does insulin treatment enhance the ability of insulin to acutely lower the AgI in type 2 
diabetic patients? (Study III) 
 
4) Is insulin resistance related to platelet sensitivity to ASA? (Study IV) 
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7 SUBJECTS AND STUDY DESIGNS 
Baseline characteristics of the study subjects are shown in Table 1. Study designs of the individual 
studies are described below. The nature and potential risks of the study were explained to all 
subjects prior to obtaining their written informed consent. The study protocols were approved by 
the ethics committee of Helsinki University Central Hospital. All studies were performed after an 
overnight fast starting at 8.00-8.30 a.m. 
 
Study I 
Dose-response study. 
Dose-response characteristics of insulin and GTN on the aortic waveform were first determined 
using applanation tonometry and pulse wave analysis in seven healthy men (age 26±1 yrs, BMI 
25±2 kg/m2). Three studies were performed in the same subjects on three separate occasions with a 
one-week interval. Each study consisted of a basal period of 1 hour, during which the 
haemodynamic measurements (peripheral and central blood pressures, the AgI, heart rate) were 
performed. The effect of sublingual GTN (500 µg, exposure time 1, 3 or 5 min in random order) 
on the AgI was then determined using pulse wave analysis with concomitant recording of central 
and peripheral blood pressures and heart rate. After the AgI returned to the baseline values and 
stabilized after a minimum of 30 min, vascular (AgI, peripheral blood flow, peripheral and central 
blood pressures) and metabolic parameters (whole body insulin sensitivity) were determined 
before and under normoglycemic hyperinsulinemic conditions (insulin infusion rate 0.5, 1 and 2 
mU/kg⋅min for 120 minutes in random order). These conditions were maintained using the 
euglycemic insulin clamp technique. 
 
Cross-sectional study. 
We compared responses to insulin (2 mU/kg⋅min for 120 min) and sublingual GTN (500 µg for 5 
min) in 20 non-diabetic subjects (age 50±2 yrs, BMI 21.0-36.3 kg/m2). The duration of the basal 
period was 1 hour, during which the haemodynamic measurements (peripheral and central blood 
pressures, the AgI, heart rate) were performed. Thereafter effects of sublingual GTN on the AgI 
was determined using pulse wave analysis with concomitant recording of central and peripheral 
blood pressures and heart rate. After the AgI had returned to baseline values and stabilized for at 
least 30 min, vascular (AgI, peripheral blood flow, peripheral and central blood pressures) 
parameters were determined basally and every 30 min under normoglycemic hyperinsulinemic 
conditions (insulin infusion rate 2 mU/kg⋅min) using the euglycemic insulin clamp technique. 
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Study II 
Sixteen type 2 diabetic patients and 19 non-diabetic subjects participated in the study. Except for 
diabetes, all participants were healthy as judged by history and physical examination, 
electrocardiogram and routine laboratory tests. Subjects with hypertension or cardiovascular disease 
(determined by electrocardiogram, history and physical examination) were excluded from the study. 
Other major systemic diseases were excluded by laboratory tests and by history and physical 
examination. The diabetic patients were recruited from diabetes outpatient clinics in Helsinki area and 
had to fulfil, in addition to the above criteria, the following: (1) age 40 to 70 years, (2) treatment with 
sulphonylurea alone or in combination with metformin, (3) no active retinopathy requiring laser 
treatment, and (4) no history of ketoacidosis. 
 
Insulin action on glucose uptake, limb blood flow and arterial stiffness were determined under 
normoglycemic hyperinsulinemic conditions, using the euglycemic insulin (insulin infusion rate 2 
mU/kg·min) clamp technique. The subjects were advised not to take any medications the previous 
evening or in the morning of the study day. Before and during the insulin infusions, metabolic and 
haemodynamic measurements (recording of the pulse wave, heart rate, blood flow and vascular 
resistance) were performed at 30 min intervals. 
 
Study III 
Thirteen type 2 diabetic patients participated in the study. Except for diabetes, the patients were 
healthy as judged by history, physical examination, ECG and routine laboratory tests. The diabetic 
patients were recruited from diabetes outpatient clinics in the Helsinki area on the basis of the 
following criteria: (1) age 40 through 70 years, (2) treatment with sulphonylurea alone or in 
combination with metformin, (3) no history of ketoacidosis, (4) and no retinopathy requiring laser 
treatment. 
 
Each patient was studied before and after 6-month combination therapy with glimepiride and 
bedtime NPH insulin. Insulin action on glucose uptake, limb blood flow and arterial stiffness were 
determined under normoglycemic hyperinsulinemic conditions, using the euglycemic insulin 
(insulin infusion rate 2 mU/kg·min) clamp technique. The patients were advised not to take any 
medications in the morning of the study day. Before and during the insulin infusions, metabolic 
and haemodynamic measurements (recording of the pulse wave, heart rate, blood flow and 
vascular resistance) were performed at 30 min intervals. 
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Study IV 
A total of 21 non-diabetic subjects were recruited for the study. The subjects were divided into an 
obese and a non-obese group by their median (29.0 kg/m2) body mass index (BMI). The subjects 
were healthy as judged by history, physical examination, ECG and routine laboratory tests, and 
were not taking any regular medications, including use of anti-inflammatory drugs, for 2 weeks 
prior to the study. Smoking was prohibited on the study day and exercise and alcohol for two days 
before the study. At the first visit, in vivo insulin action was measured by using the euglycemic 
insulin clamp technique. At the second visit (2-7 days after the first visit) the blood samples for 
aggregation tests were withdrawn before and one hour after administration of a tablet containing 
50 mg ASA chewed by the patient.  
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8 METHODS 
8.1 Whole body glucose uptake 
Whole body insulin sensitivity was determined by using the euglycemic insulin clamp technique.94 
The studies were performed after an overnight fast starting at 8.00 a.m. An 18-gauge catheter 
(Venflon; Viggo-spectramed, Helsingborg, Sweden) was inserted into the left antecubital vein for 
infusion of glucose and insulin. Another 18-cauge catheter was inserted retrogradely in a dorsal 
hand vein. This hand was kept in a heated chamber (65º C) for sampling of arterialized venous 
blood as previously described.365 Insulin (Actrapid Human, Novo Nordisk, Copenhagen, 
Denmark) was infused in a primed-continuous fashion for 180 min (study II, III and IV) or 120 
(study I) min. The rate of the continuous insulin infusion was 0.5, 1 and 2 mU/kg·min (study I 
dose-response) or 2 mU/kg·min (study I cross-sectional, II and IV). The amount of 20 % glucose 
infused to maintain normoglycemia during hyperinsulinemia was based on plasma glucose 
concentrations measured at 5 minute intervals. Whole body insulin sensitivity (the M-value, 
mg/kg⋅min) was calculated from the glucose infusion rate after correction for changes in glucose 
pool size at 30 minute intervals.  Blood samples were taken at 30 minute intervals for 
measurements of serum free insulin concentrations. 
 
8.2 Forearm blood flow and peripheral vascular resistance 
Forearm blood flow (study I, II and III) was measured at baseline and every 30 min during the 
euglycemic hyperinsulinemic clamp with venous occlusion plethysmography using a mercury in 
silastic rubber strain gauge (Model EC-4, Hokanson, Bellevue, WA) as previously described.365 
The gauge was attached around the widest, most muscular segment of the right forearm. Before 
flow measurements, circulation to the hand was interrupted by inflating a pediatric blood pressure 
cuff around the wrist to above the systolic blood pressure.  Venous return was occluded by a rapid 
cuff inflation (Rapid Cuff Inflator model E20, Hokanson) by increasing pressure in a 
sphygmomanometer cuff around the upper arm to 50 mmHg. Several blood flow curves were 
recorded with the use of an analog-to-digital converter (MacLab / 4e, AD Instruments, Castle Hill, 
Australia) connected to a personal computer. At least five flow curves were recorded for each flow 
measurement. Arterial inflow was determined with the use of computerized analysis of flow 
curves by drawing a tangential line few pulses following cuff inflation. The slope of this line 
reflects the volume change per unit time. Calibration was performed with the use of the built-in 
electronic calibration signal for a 1 per cent volume change, the height of which is used for blood 
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flow calculations. Peripheral vascular resistance was calculated by dividing mean arterial pressure 
in the brachial artery by forearm blood flow. 
 
8.3 Pulse wave analysis 
The technique of pulse wave analysis was used to determine central aortic pressure and the AgI 
(study I, II and III) as previously described in detail.265; 393 All measurements were made from the 
radial artery, with the wrist slightly extended and supported on a pillow by applanation tonometry 
using a Millar tonometer (SPC-301; Millar Instruments, Houston, TX) basally and every 30 
minutes during the insulin infusion. Data were collected directly into a desk top computer and 
processed with SphygmoCor Blood Pressure Analysis System (BPAS-1; PWV Medical, Sydney, 
Australia), which allows continuous on-line recording of the radial artery pressure waveform. The 
radial waveform was assessed visually to ensure that artefacts from movement and respiration were 
minimized. Recordings for pulse wave analysis were made twice basally and every 30 minutes 
during insulin infusions. The mean of 3 measurements, each consisting of 15 to 20 sequential radial 
artery waveforms, was used to calculate augmentation and other parameters at the given time 
point. 
 
In study I the effect of sublingual GTN (500 µg, Cox Pharmaceuticals, Barnstaple, UK; exposure 
time 1, 3 or 5 min) on the AgI was then determined using pulse wave analysis with concomitant 
recording of central and peripheral blood pressures and heart rate. Insulin clamp study was started 
after the AgI had returned to the baseline values and stabilized after a minimum of 30 min, In 
studies I, II and III, vascular (AgI, peripheral blood flow, peripheral and central blood pressures) 
parameters were determined before and under normoglycemic hyperinsulinemic conditions. The 
integral system software was used to calculate an average radial artery waveform, and to generate the 
corresponding ascending aortic pressure waveform using a transfer function (Fig. 8).61; 170 The 
transfer function has been validated recently for the present device by comparing the derived the 
AgI to that measured simultaneously invasively by recording of central pressure in 62 patients 
going through coronary bypass surgery.281 
 
Wave transmission properties in the upper limbs (in contrast to the descending aorta and lower 
limbs) change little with age, disease, and drug therapy in adults.258 As suggested by O'Rourke and 
Gallagher,265 the radial pressure was calibrated against the sphygmomanometrically determined 
brachial pressure, ignoring the small degree of amplification between the brachial and radial sites. 
 44
The aortic waveform was then subjected to further analysis for calculation of aortic augmentation (the 
pressure difference between the second and first systolic pressure peaks), the AgI, ejection duration 
and central systolic and diastolic blood pressure. The AgI was calculated by dividing augmentation 
with pulse pressure (Fig. 4).178; 265 Ejection duration was determined as a time period from the start of 
the pulse wave until the closure of the aortic valve detected as an incision in the aortic pressure wave. 
In studies I, II, III and IV blood pressure was measured with a calibrated sphygmomanometer and 
basal value was measured twice after a ten-minute bed rest. 
 
 
Figure 8. Radial (left panel) and aortic (right panel) waveforms from pulse wave analysis.  
 
8.4 Insulin treatment 
Type 2 diabetic patients considered eligible to participate in study III met with the doctor and the 
diabetes nurse 6 weeks before the start of insulin therapy. At this visit, the patients underwent 
complete history and physical examination. The patients were instructed to measure their fasting 
blood glucose concentrations and to record any episodes of hypoglycemia. The patients then visited 
the laboratory for measurement of fasting blood glucose, HbA1C, serum concentrations of creatinine 
 45
and liver enzymes. An electrocardiogram was recorded and the urinary albumin excretion rate 
measured before start of insulin therapy. The results of the laboratory tests were checked, and if 
acceptable, all previous antidiabetic drugs were stopped and the patients were treated with 3 mg 
glimepiride for three weeks before the start of insulin therapy. Thereafter the patients were treated 
with combination therapy consisting of bedtime human isophane insulin (NPH) and continued 
glimepiride. The patients were taught self-adjustment of the insulin dose on the basis of plasma 
glucose measurements. The patients were instructed to increase their bedtime NPH dose by 2 units if 
the fasting glucose exceeded 6 mmol/l on three consecutive mornings. The patients visited the 
hospital outpatient clinic monthly. The pulse wave analysis and determination of whole body insulin 
sensitivity were performed after the outpatient visits at 6 months. 
 
8.5 The effect of ASA on platelet aggregation 
The platelet studies were performed after an overnight fast starting at 8.00–8.30 a.m. The subjects 
(study IV) were not taking any regular medications, including anti-inflammatory drugs, for 2 
weeks prior to the study. Smoking was prohibited on the study day and exercise and alcohol for 
two days before the study. Blood for the initial aggregation test was collected from median 
antecubital vein via an 18-gauge catheter. The patient thereafter chewed and swallowed a 50 mg 
tablet of ASA (Disperin 50 mg, Orion, Finland) with some water. After 60 minutes, another 
catheter was inserted in an intact antecubital vein for sampling of blood for repeated aggregation 
measurements. Blood for platelet aggregation measurements was collected into tubes containing 
0.129 M sodium citrate (9:1) and centrifuged (170 x g, 12 min at 22° C) to obtain platelet rich 
plasma (PRP). Platelet-poor plasma (PPP) was prepared by centrifugation of PRP at 5000 x g for 5 
min. The concentration of platelets in PRP was determined by a cell counter (Sysmex K-1000, 
TOA Medical Electronics, Japan) and adjusted to 300 x 106/ml with autologous PPP. PRP and PPP 
were stored in capped plastic tubes and kept in room temperature. 
 
In vitro platelet aggregation in PRP was measured using a four-channel turbidometric 
aggregometer (PACKS-4, Helena Laboratories, Beaumont, TX).50 The aggregating agents were 
ADP (final concentrations 1, 1.5, 2 and 3 µmol/l; Sigma Chemicals, St. Louis, MI) and AA (final 
concentrations 0.5, 0.75, 1 and 1.5 mmol/l; Sigma Chemicals, St. Louis, MI). The samples were 
stirred at 600 rpm and preincubated for 1 minute at 37°C before the addition of the aggregating 
agent. The maximal aggregation (%) response at each concentration of the agonist was determined 
at baseline and after 50 mg oral ASA (Fig. 9). 
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8.6 Body composition 
Fat free mass (FFM) and the percent of body fat were determined using bioelectrical impedance 
analysis (BioElectrical Impedance Analyzer System model #BIA-101A; RJL Systems, Detroit, 
MI).225 The prediction equation used for estimating fat free mass (FFM; kg) was: 
FFM= 13.74 + 0.34·(Ht2/R2)+0.33·Wt-0.14·Age+6.18·gender 
 
Where height (Ht) is expressed in cm, resistance (R) in W, weight (Wt) in kg, and age in yr; for 
gender a value 1 is given for males and 0 for females.299 To calculate the W/H, waist 
circumference (W) was measured midway between spina iliaca superior and the lower rib margin, 
and hip circumference (H) at the level of the greater trochanters.403 
 
Figure 9. Aggregation with four doses of arachdonic acid before (upper panel) 
and after (lower panel) 50 mg ASA. 100% denotes fullblown aggregation.  
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8.7 Analytical procedures 
Plasma glucose concentrations were measured in duplicate with the glucose oxidize method using 
a Beckman Glucose analyzer II (Beckman Instruments, Fullerton, CA).163 Serum free insulin 
concentrations were measured by radioimmunoassay (Phadeseph® Insulin RIA, Pharmacia & 
Upjohn Diagnostics, Uppsala, Sweden) after precipitation with polyethylene glycol98 and C-
peptide concentrations using time-resolved fluoroimmunoassay (AUTOdelfiaTM C-peptide, 
Wallac, Turku, Finland). HbA1C was measured by high pressure liquid chromatography using the 
fully automated Glycosylated Hemoglobin Analyzer System (BioRad, Richmond, CA).335 Serum 
total, HDL cholesterol and triglyceride concentrations were measured with respective enzymatic 
kits from Roche Diagnostics using an autoanalyzer (Roche Diagnostics Hitachi 917, Hitachi Ltd, 
Tokyo, Japan). Low density lipoprotein (LDL) concentration was calculated using the formula of 
Friedewald. Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma 
glutamyl transferase (GGT) activities were determined as recommended by the European 
Committee for Clinical Laboratory Standards. 
 
8.8 Statistical methods 
The unpaired t-test was used to compare mean values between groups (study I, II and IV) and the 
paired t-test to compare selected variables before and after intervention (study III), after 
logarithmic transformation if necessary. Spearman’s non-parametric rank correlation coefficient 
was used to calculate correlation coefficients between selected variables (study I, II, III and IV). 
Parameters, which were not normally distributed, were log-transformed. Calculations were made by 
GraphPad Prism version 3.0 (GraphPad Inc, San Diego, CA). The best fit characterizing the 
relationship between haemodynamic parameters over time and corresponding 50% effective 
dose/exposure time of the curves were determined by comparing the goodness of fit of linear and 
multiple non-linear equations using GraphPad Prism. Analyses of ASA effects at various agonist 
concentrations between lean and obese subjects (study IV) and changes in haemodynamic 
parameters over the time (study II, III and IV) were made using analysis of variance (ANOVA) for 
repeated measures using the SYSTAT statistical package (Evanston, IL) followed by Bonferroni’s 
multiple comparisons test. The results are expressed as mean±standard error of mean. All p-values 
are 2-tailed. P-values less than 0.05 were considered statistically significant. 
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9 RESULTS 
9.1 Comparison of in vivo effects of GTN and insulin (Study I) 
Dose-response study 
Effects of GTN. The AgI averaged 0.5±2.0, -0.1±2.5 and -1.6±2.0 % at baseline before GTN exposure 
of 1, 3 and 5 min (NS). The AgI decreased significantly after all exposures to maximally -9.6±1.7, 
 -10.6±1.7 and -15.7±2.2 %, respectively. From the best fit for the dose -response curve, the 50 % 
effective exposure time for GTN to decrease the AgI was 44 s (Fig. 10). 
 
Effects of insulin. During the insulin infusions serum free insulin concentrations increased from 6±2, 
5±1 and 5±1 mU/l basally to 30±2, 62±2 and 156±4 mU/l between 30-120 min during the 0.5, 1 and 2 
mU/kg⋅min insulin infusions. Plasma glucose concentrations averaged 5.5±0.2, 5.4±0.2 and 5.4±0.2 
basally and 5.1±0.1, 5.0±0.1 and 5.0±0.1 mmol/l during insulin infusions, respectively. Whole body 
glucose uptake averaged 5.4±0.9, 7.6±0.9 and 10.5±1.2 mg/kg⋅min, respectively (Fig. 10). The AgI 
averaged 0.7±1.7, -0.3±2.3 and -0.9±2.0 % at baseline before insulin infusions of 0.5, 1 and 2 
mU/kg⋅min (NS). The AgI decreased significantly within 60 min during the insulin infusion rates of 
0.5 (-6.3±2.8 %, p<0.05) and 1 (-6.2±2.2 %, p<0.01) mU/kg⋅min and already at 30 min during the 2 
mU/kg⋅min insulin infusion (-5.0±1.0 %, p<0.05). The maximal insulin-induced decrease in the AgI 
averaged -8.0±2.7, -10.2±1.8 and -13.4±1.8 % (p=0.001 for slope relating change in AgI to insulin 
dose), respectively. From the best fit for dose-response curve, the 50 % effective dose for insulin to 
decrease the AgI was 0.6 mU/kg⋅min. 
 
During the insulin infusions, aortic pressure augmentation (i.e. the pressure difference between the 
first and second systolic pressure peaks at the level of the aorta) decreased significantly during 60 min 
with insulin infusion rates of 0.5 (0±1 vs. -2±1 mmHg, 0 vs. 60 min, p<0.05) and 1 (0±1 vs. -2±1 
mmHg, 0 vs. 60 min, p<0.05) mU/kg⋅min and already at 30 min during 2 mU/kg⋅min insulin infusion 
(0±1 vs. -2±1 mmHg, 0 vs. 30 min, p<0.05). Heart rate remained unchanged during all studies (59±1 
vs. 58±1, 58±2 vs. 59±2 and 58±2 vs. 61±2 beats/min 0 vs. 120 min during 0.5, 1 and 2 mU/kg⋅min 
insulin infusions). There were no changes in peripheral blood flow during the insulin infusions of 0.5 
and 1 mU/kg⋅min. During the highest insulin dose, the AgI decreased significantly (p<0.001) by 30 
min. A 31% increase in peripheral blood flow was observed at 2 hours (p<0.05), but not at any other 
time point. 
 
 49
Brachial artery systolic blood pressure did not change during the 0.5 mU/kg⋅min insulin infusion 
(118±4 vs. 117±4 mmHg, 0 vs. 120 min, NS), but increased significantly at 120 min during the 
insulin infusion of 1 mU/kg⋅min, (113±3 vs. 116±3 mmHg, 0 vs. 120 min, p<0.01) and 2 
mU/kg⋅min (114±3 vs. 120±4 mmHg, 0 vs. 120 min, p<0.01). Brachial artery diastolic blood 
pressure did not change during 0.5 mU/kg⋅min insulin infusion (64±2 vs. 63±2 mmHg, 0 vs. 120 
min, NS). Brachial artery diastolic blood pressure decreased significantly at 90 min during the 
insulin infusion of 1 mU/kg⋅min, (62±1 vs. 60±2 mmHg, 0 vs. 90 min, p<0.01) and at 120 min 
using 2 mU/kg⋅min insulin infusion (63±2 vs. 59±1 mmHg, 0 vs. 120 min, p<0.05). In contrast to 
changes in peripheral blood pressures, both aortic systolic and diastolic blood pressure remained 
unchanged during all three insulin infusions. 
 
Cross-sectional study 
The AgI. After 5 min sublingual GTN, the AgI decreased significantly from 25.2±2.5 to 6.4±2.7 % 
(p<0.0001). During the insulin infusion serum free insulin concentrations increased from 10±2 basally 
to 171±6 mU/l between 30-120 min. Plasma glucose concentrations were maintained at 5.1±0.1 
mmol/l during the insulin infusion. Whole body glucose uptake averaged 5.1±0.5 mg/kg⋅min (range 
1.0-8.6 mg/kg⋅min). During the insulin infusion, the AgI decreased significantly by 30 min (19.7±3.0 
vs. 15.7±3.1 %, 0 vs. 30 min, p<0.0001). The maximal insulin-induced decrease in the AgI averaged 
11.7±3.6 %, p<0.0001. The change in the AgI by GTN and insulin were significantly positively 
correlated (Spearman’s r=0.92 (95% confidence interval 0.81-0.97), p<0.0001, Fig. 11). There was no 
correlation between basal AgI and change in the AgI by either insulin or GTN. Adjustment for age 
(after adjustment r=0.93 between change in AgI by GTN and insulin, p<0.0001) or gender (after 
adjustment r=0.92, p<0.001) did not change the results. The correlation coefficient between the 
change in AgI by insulin and GTN was 0.96 (p<0.0001) in women and 0.90 (p<0.0001) in men. 
 
Other haemodynamic effects. GTN decreased aortic pressure augmentation significantly from 10±2 to 
a nadir of 3±1 mmHg (p<0.001). Heart rate remained unchanged (62±2 vs. 63±2 beats/min, basal vs. 
nadir). Brachial artery systolic blood pressure did not change by GTN (128±3 vs. 127±3 mmHg) but 
decreased significantly at the level of the aorta from 119±4 at baseline to a nadir of 112±3 mmHg 
(p<0.001). 
 
 
 50
Insulin decreased aortic pressure augmentation significantly by 30 min (7±1 vs. 5±1 mmHg, 0 vs. 30 
min, p<0.01). Heart rate remained unchanged during the insulin infusion (61±2 vs. 60±2 beats/min 0 
vs. 120 min). Peripheral blood flow increased significantly by 120 min (1.7±0.1 vs. 2.0±0.1 
ml/dl⋅min, 0 vs. 120 min, p<0.05). Brachial artery systolic blood pressure did not change during 
insulin infusion (122±3 vs. 121±3 mmHg, 0 vs. 120 min), but decreased significantly at the level of 
the aorta at 30 min (111±3 vs. 107±3 mmHg, 0 vs. 30 min, p<0.01). 
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Figure 10. Whole body glucose uptake (upper panel) and change in the AgI (middle panel) during 
2-hour insulin infusions of 0.5, 1 and 2 mU/kg⋅min, and change in the AgI after sublingual GTN 
(500 µg) for 1, 3 and 5 minutes. Euglycemia was maintained using the euglycemic insulin clamp 
technique. 
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Figure 11. Relationship between percentage change in the AgI by sublingual GTN (500 µg for 5 
min) and insulin infusion of 2 mU/kg⋅min. R denotes Spearman’s non-parametric correlation 
coefficient, CI denotes confidence interval. 
 
 
9.2 The effect of insulin on the AgI and central blood pressure in type 2 
diabetes (Study II) 
Glucose and insulin concentrations, insulin sensitivity 
Fasting plasma glucose concentrations averaged 5.7±0.1 mmol/l in normal subjects and 11.6±0.7 in 
type 2 diabetic patients, p<0.001. Fasting serum free insulin concentrations were 11±2 mU/l in both 
groups. During the insulin infusions, serum free insulin concentrations averaged 170±7 mU/l in the 
normal subjects, and 167±7 mU/l in the patients with type 2 diabetes (NS). During the last hour of 
hyperinsulinemia, plasma glucose averaged 5.1±0.1 mmol/l in the normal subjects, and 5.3±0.1 
mmol/l in the patients with type 2 diabetes (NS). Whole body insulin sensitivity of glucose 
metabolism (M-value 150-180 min) was 31 % lower in patients with type 2 diabetes (4.8±0.6 mg/kg⋅
min) than in the normal subjects (7.0±0.6 mg/kg⋅min, p<0.05). 
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Augmentation and the augmentation index 
Augmentation averaged 8.9±1.3 mmHg at baseline in the normal subjects, and decreased significantly 
within 30 minutes to 6.1±1.1 mmHg (p<0.001 vs. basal), and after 180 minutes to 5.5±1.2 mmHg. 
(p<0.001 vs. basal). The AgI averaged 23.1±2.1% at 0 min and decreased significantly and by 30 % 
after 30 min to 17.9±2.6 %, (p<0.001 vs. basal) and after 180 min to 14.9±3.0 % (Fig. 13). The 
decrease during first hour also could not be attributed to a decrease in peripheral vascular resistance 
since both forearm blood flow (1.8±0.2 vs. 1.7±0.1 ml/dl⋅min, 0 vs. 60 min, NS) and peripheral 
vascular resistance (64±7 vs. 54±4 mmHg/ml/dl⋅min, respectively, NS) remained unchanged. 
 
Basally, before the insulin infusion, augmentation and the AgI were comparable between type 2 
diabetic patients and normal subjects. In contrast to the normal subjects, however, augmentation did 
not decrease significantly by insulin in the diabetic patients during the first 30 minutes. Mean 
augmentation averaged 11.1±1.2 mmHg basally and 9.1±1.1 mmHg after 30 minutes (NS vs. basal) 
(Fig 13). The first significant decrease in augmentation was observed at 60 min in the patients with 
type 2 diabetes, 8.5±1.0 mmHg (p<0.05 vs. basal). Minimum augmentation was reached after 180 
minutes of insulin infusion, when it averaged 7.2±1.0 mmHg (p< 0.001 vs. basal). (Fig. 13). The 
percent change in augmentation was significantly smaller in the patients with type 2 diabetes than in 
the normal subjects at 30 minutes (-17±6 % vs. -36±7 %, p<0.05).  Basally, the AgI averaged 27.5±
2.1 % in the diabetic patients. The AgI decreased to 24.4±2.2 % at 30 minutes (p<0.01 vs. basal) and 
reached minimum at 180 minutes 19.1±2.7 % (p<0.001 vs. basal). There was a significantly smaller 
percent change in the AgI in the diabetic patients than in normal subjects at 30 minutes (-13±4% vs. -
30±7%, p<0.05) and at 60 minutes (-16±5% vs. -39±9%, p<0.05). The decrease was significantly 
lower in the diabetic than non-diabetic group independent of basal AgI. There were no significant 
correlations between insulin sensitivity and augmentation or the AgI or their changes by insulin and in 
either group. 
 
Central and peripheral systolic blood pressures 
As expected from the change in augmentation and the AgI (Fig. 13), systolic aortic blood pressure 
decreased significantly in the normal subjects by 30 minutes, while there was no significant change in 
systolic aortic blood pressure at this time point in the type 2 diabetic patients (Fig. 12). Aortic systolic 
blood pressure remained significantly lower than at baseline for the entire period of hyperinsulinemia 
in the normal subjects (Fig. 12). In the type 2 diabetic patients, a significant decrease in aortic systolic 
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blood pressure was not observed until 120 minutes of hyperinsulinemia (Fig. 12). Brachial systolic 
pressure did not change significantly in either group (Fig. 12). 
 
Other haemodynamic parameters 
Heart rate remained unchanged in both groups during the 180 min period of insulin infusion (data not 
shown). A small (21 %) increase in peripheral blood flow was observed at 180 min in the normal 
subjects (1.8±0.2 vs. 2.2±0.2 ml/dl·min, p<0.05) and this was associated with a significant decrease in 
brachial artery diastolic pressure at 150 (-2.7±1.0 mmHg, p<0.05) and 180 min (-3.7±0.9 mmHg, 
p<0.01) compared to basal diastolic pressure (80±2 mmHg). Forearm blood flow and diastolic 
pressure remained unchanged in the type 2 diabetic patients (data not shown).  
 
 
 
Figure 12. Peripheral (circles) and aortic (squares) systolic blood pressure in the normal subjects 
(open symbols) and the type 2 diabetic patients (filled symbols). + p<0.05, ++ p<0.01, 
 +++ p<0.001 for change vs. 0 min. 
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Figure 13. The AgI and augmentation during 180 min of hyperinsulinemia. The open circles (o) 
denote normal subjects and the filled circles (•) type 2 diabetic patients. * p<0.05 for the 
difference of change in the AgI or augmentation between the groups. + p<0.05, ++ p<0.01, 
 +++ p<0.001 for change vs. 0 min. 
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9.3 The effect of insulin therapy on glucose metabolism, the AgI and central 
blood pressure in type 2 diabetes (Study III) 
 
Metabolic effects of insulin therapy 
Metabolic effects of insulin therapy have been summarized in Table 2. The mean bedtime insulin 
dose at 6 months was 76±10 IU/day. HbA1C decreased from 8.8±0.2 to 7.2±0.2 % (p<0.001) and 
body weight increased from 96±4 to 102±5 kg (p<0.01) during the six month insulin therapy. 
 
Glucose and insulin concentrations and insulin sensitivity of glucose metabolism 
Fasting plasma glucose and serum free insulin concentrations are given in Table 2. During the insulin 
infusion (30-180 min), serum free insulin concentrations were comparable before and after insulin 
treatment. During the last hour (120-180 min) of hyperinsulinemia plasma glucose averaged 5.4±0.2 
mmol/l before insulin treatment and 5.1±0.1 mmol/l after insulin treatment (NS). Insulin treatment 
increased insulin sensitivity by 35 % from 5.1±0.7 to 6.8±0.6 mg/kg ffm⋅min (p<0.001). 
 
Insulin action on wave reflection, blood pressure and other haemodynamic parameters 
Six months of insulin therapy decreased basal AgI from 26.2±1.8 to 22.7±2.3% (p<0.05). Insulin 
acutely decreased AgI progressively until 120 minutes both before and after insulin therapy. The 
change in the AgI by insulin was similar before and after insulin therapy at all time points (Fig. 14). 
During insulin infusion brachial systolic blood pressure was unchanged both before and after insulin 
therapy. Mean arterial pressure measured before insulin infusion was similar before and after 6 
months of insulin therapy (98 ± 2 vs. 97 ± 2 mmHg). Mean arterial pressure decreased 
significantly by 120 min of insulin infusion with no significant difference in the change of mean 
arterial pressure before and after 6 months of insulin therapy. Consistent with the decrease in the 
AgI, aortic systolic blood pressure decreased similarly acutely by insulin both before and after insulin 
therapy (Fig. 15). Peripheral blood flow, pulse pressure, heart rate and ejection duration were similar 
before and after insulin treatment and remained unchanged during the insulin infusion (data not 
shown). 
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Table 2. Metabolic effects of 6 months of insulin therapy 
 Type 2 diabetic patients before 
insulin therapy 
Type 2 diabetic patients 
after insulin therapy 
Men/women 11/2  
Age (years) 53±2  
Height (cm) 176±2  
Weight (kg) 96±4 102±5** 
Body mass index (kg/m2) 30.8±1.2 32.7±1.5** 
Body fat (%) 29±2 30±1 
Systolic blood pressure (mmHg) 132±4 130±3 
Diastolic blood pressure (mmHg) 80±2 80±2 
Waist/hip ratio 1.02±0.02 1.02±0.02 
Fasting plasma glucose (mmol/l) 12.5±0.8 7.1±0.5*** 
Fasting serum insulin (mU/l) 11±2 28±4** 
SSSI1 (mU/l) 177±7 197±14 
HbA1C (%) 8.8±0.2 7.2±0.2*** 
Serum cholesterol (mmol/l) 5.3±0.3 5.3±0.4 
Serum HDL cholesterol (mmol/l) 1.1±0.1 1.1±0.1 
Serum triglycerides (mmol/l) 1.9±0.2 1.9±0.3 
 
Data are shown as mean±SEM. **p<0.01, ***p<0.001 for difference between before and after 
insulin treatment in diabetic patients, 1SSSI = steady-state serum free insulin concentration (30-
180 min, mU/l). 
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Figure 14. Augmentation and AgI before and after insulin therapy. * p<0.05, ** p<0.01, 
 *** p<0.001 for change vs. 0 min. 
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Figure 15. Brachial and aortic systolic blood pressure before and after insulin therapy. *p<0.05, 
** p<0.01, *** p<0.001 for change vs. 0 min. 
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9.4 The effect of ASA on platelet aggregation in obese and non-obese subjects 
(Study IV) 
Whole body insulin sensitivity 
During the insulin infusion, serum free insulin concentrations averaged 182±14 in the obese and 
164±8 mU/l in the non-obese group (NS). Plasma glucose averaged 5.1±0.1 mmol/l in both groups 
during hyperinsulinemia. Whole body insulin sensitivity was 36 % lower in the obese (4.5±0.6) 
than the non-obese (7.1±0.6 mg/kg⋅min, p<0.01) group. Both BMI (r=-0.73, p<0.001), body 
weight (r=-0.60, p<0.01), the waist/hip ratio (r=-0.43, p<0.05), and concentrations of fasting serum 
insulin (r=-0.76, p<0.001), C-peptide (r=-0.86, p<0.001), serum triglycerides (r=-0.53, p<0.05) and 
HDL cholesterol (r=0.49, p<0.05) were significantly correlated with whole body insulin 
sensitivity. 
 
Platelet aggregation 
Before ASA administration already the lowest concentration of AA (0.5 mmol/l) induced maximal 
aggregation in each subject without any differences between the groups (95±1 % vs 94±2 %, obese 
vs non-obese, NS). In the blood sample taken one hour after 50 mg ASA, AA-induced aggregation 
was inhibited by ASA in the obese group only at the lowest dose of AA, while ASA significantly 
inhibited aggregation at all doses of AA in the non-obese group (Fig. 16). Maximal aggregation 
after ASA was significantly greater in the obese than the non-obese group (p=0.016 for ANOVA, 
Fig.16). 
 
Before ASA, when ADP was used as the agonist, aggregation in response to the two lowest 
concentrations of ADP was slightly but not significantly greater in platelets of the obese than those 
of the non-obese group (Fig. 16). Aggregation was significantly more inhibited by ASA at ADP 
concentrations of 2 µmol/l (74±6 vs 91±1 % in non-obese vs obese, p<0.01) and 3 µmol/l (79±6 vs 
93±1 %, respectively, p<0.05) in the non-obese than the obese group (Fig. 16). 
 
Before ASA administration, whole body insulin sensitivity in the whole study group was inversely 
correlated with aggregation induced by the two lowest doses of ADP (1 and 1.5 µmol/l, Table 3). 
After ASA ingestion, there was a strong negative correlation between insulin sensitivity and 
maximal aggregation induced by AA at concentrations of 0.75, 1, 1.5 mmol/l, and ADP at 
concentrations of 1.5 and 3 µmol/l (Table 3). Aggregation induced with 1 mmol/l AA after ASA 
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also correlated with BMI, body weight, waist/hip ratio, serum triglycerides, C-peptide and fasting 
serum insulin as well as with ADP induced aggregation both before and after ASA administration. 
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Figure 16. Maximal aggregation at four concentrations of AA (a) and ADP (b) at baseline and 
after ASA 50 mg. * p<0.05, **p<0.01, ***p<0.001 for obese vs non-obese after ASA 50 mg. 
 + p<0.05, ++p<0.01, +++p<0.001 for difference between aggregation at baseline and after ASA. 
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Table 3. Correlations between insulin sensitivity (mg/kg⋅min) determined by the euglycemic 
clamp technique and maximal aggregation with different concentrations of AA and ADP in the 
whole study group. 
 
 r p 
AA 0.75 mmol/l after ASA -0.67 <0.001 
AA 1 mmol/l after ASA -0.68 <0.001 
AA 1.5 mmol/l after ASA -0.63 <0.001 
ADP 1 µmol/l   at baseline -0.48 <0.05 
ADP 1.5 µmol/l   at baseline -0.48 <0.05 
ADP 1.5 µmol/l after ASA -0.52 <0.05 
ADP 3 µmol/l after ASA -0.45 <0.05 
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10 DISCUSSION 
 
The present studies were made to investigate the connections between insulin resistance and 
insulin action on arteries and ASA action on platelets. There are interesting parallels between 
insulin action on vessels and platelets.356 Both vascular synthesis of prostacyclin (PGI2) and 
platelet sensitivity to PGI2 may be diminished in diabetes.10; 136 Insulin promotes endothelium-
dependent vasodilatation373 and inhibits platelet aggregation.359 Insulin actions on platelet 
aggregation and the AgI are impaired in insulin resistant subjects.21; 357; 388; 392 Insulin-induced 
vasodilatation and insulin-induced inhibition of platelet aggregation can both be blocked by L-
NMMA.314; 333; 358 Both peripheral resistance arteries229 and platelets21 have been reported to have 
diminished sensitivity to NO in patients with type 2 diabetes229 and in obese non-diabetic as 
compared to age-matched normal-weight subjects.21; 366 In study I we also found a correlation 
between the action of insulin and GTN on large artery function. Impaired bioavailability of NO, 
due to diminished synthesis, increased destruction or insensitivity of effector pathways, could thus 
be a common defect predisposing insulin resistant individuals to abnormalities in vascular and 
platelet functions. 
 
STUDIES I, II and III 
In the studies I, II and III, we studied large artery function with pulse wave analysis. In study I we 
found insulin and GTN to decrease the AgI in dose-dependent manner and that the actions of 
insulin and GTN on the AgI were closely correlated. In study II we found that the insulin action on 
the AgI was impaired in type 2 diabetic patients when compared to age and weight matched 
normal subjects. In study III we found that 6 months of basal insulin therapy decreases the AgI but 
does not alter the change of AgI induced by insulin infusion. In the studies II and III, insulin 
sensitivity of glucose metabolism within the group of type 2 diabetic patients or their matched 
control subjects did not correlate with the insulin-induced change of the AgI, although such 
relationship has been found in previous studies in both non-diabetic men390 and a group of obese 
subjects.392 In a previous study of non-diabetic group including a total of 50 men with BMIs 
ranging from 19 to 45 kg/m2 and age from 18 to 60 years there was a correlation between insulin 
sensitivity and both basal AgI and the change in AgI by insulin infusion.390 This group was larger 
than present study groups and had a larger variation in both basal AgI, its change by insulin and in 
insulin action on glucose metabolism than in the present studies. 
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Previous studies have uniformly found endothelium-dependent vasodilatation in the peripheral 
resistance arteries of type 2 diabetic patients to be impaired. In addition, endothelium-independent 
vasodilatation has been impaired in some of the studies.231 Insulin does have a sluggish 
vasodilatating effect on peripheral resistance vessels.196; 415 For example, while acetylcholine, a 
classic endothelium-dependent vasodilatator, or sodium nitroprusside increase blood flow at 
submaximal doses at least 500 % above basal within a minute, it takes even in young healthy 
normal subjects 120 min before insulin significantly increases peripheral blood flow and even 
then, the increase is only 20-80 %. In the present, as well as previous studies,11; 390; 392; 393 the 
changes in the AgI occurred within 30-60 minutes at physiological insulin concentrations, unlike 
in peripheral resistance vessels where the effect of insulin occurs after several hours of 
supraphysiological concentrations.415 
 
In studies I, II and III, peripheral vascular resistance, heart rate and brachial systolic and diastolic 
blood pressure remained unchanged during the time period when the changes in augmentation 
occurred. In study II there was a small increase in peripheral blood flow in normal subjects but not 
in diabetic subjects at 180 minutes. In study I there was an increase in peripheral blood flow in 
both dose-response and cross-sectional study at 120 minutes at insulin infusion rate 2 mU/kg⋅min. 
At the higher insulin doses (2-5 mU/kg·min), peripheral systolic blood pressure increases slightly 
and diastolic blood pressure decreases concomitant with peripheral vasodilatation.393 Changes in 
blood pressure at supraphysiological insulin concentrations415 are likely to be a consequence of 
activation of the sympathetic nervous system in response to peripheral vasodilatation.393 The 
decrease in wave reflection by insulin could thus have been due to an acute decrease in the tone of 
muscular arteries greater than those controlling peripheral vascular resistance. Alternatively, it 
could have been due to a change in elastic properties of the aorta, although given the rapid time 
course, this possibility seems unlikely. 
 
In the studies I cross-sectional, II and III, the AgI was positive i.e. pressure of the reflected wave 
was higher than that of the first systolic pressure wave prior to start of the insulin infusion. The 
higher AgI was most likely explained by age-associated stiffening of arteries in these subjects, 
who averaged 50 years of age.178 In studies I cross-sectional, II and III, insulin not only decreased 
the AgI but also central systolic pressure within 30 min in normal subjects and between 60 and 120 
minutes in type 2 diabetic patients. Brachial systolic blood pressure remained unchanged in all 
groups. In previous studies, where only young healthy volunteers were studied,11; 391-393 insulin did 
not decrease central systolic pressure because baseline augmentation was negative. 
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Pulse pressure, a surrogate measure of arterial stiffness, varies throughout the arterial tree, in part 
because of differences in vessel compliance and the phenomenon of wave reflection. Normally 
there is amplification of pulse pressure from the aorta to the periphery, mainly caused by a rise in 
systolic blood pressure, whereas diastolic pressure and mean arterial pressure are relatively 
constant.398 Especially in young subjects high brachial systolic blood pressure may be a sign of 
systolic hypertension or great pulse wave amplification due to flexible arteries. With increasing 
age arterial stiffness increases and the difference between central and peripheral systolic blood 
pressure decreases. Wave transmission properties of the upper limb change little with age or 
disease in humans, which enables the use of a generalized transfer function to synthesize the aortic 
waveform from those recorded in the periphery.258 The transfer function and the device used to 
record radial artery waveforms used in the present studies were recently validated by invasive 
measurements in 62 patients undergoing cardiac surgery.281 
 
In the present studies, the radial blood pressure was calibrated against the sphygmomanometrically 
determined brachial blood pressure as suggested by O’Rourke at al 265 thus ignoring the small 
amplification between these sites. When calibrated against invasively measured aortic blood 
pressure, there is a strong correlation between central blood pressures and the AgI measured 
invasively and non-invasively from the radial artery using a generalized transfer function.281 When 
calibrated against blood pressure measured with a sphygmomanometer from the brachial artery, 
the central blood pressures derived from radial measurements are accurate, but the AgI does not 
correlate well with the AgI measured invasively147 or from carotid artery without the use of a 
transfer function.250 Therefore some authors consider direct carotid artery AgI measurement250; 269 
or even the AgI measured at radial artery without use of transfer function to be a better measure of 
wave reflection than the AgI measured with the help of a transfer function.147 However, in the 
study criticizing use of the transfer function blood pressures were measured oscillometrically 
rather than using the auscultatory method.250 Oscillometric measurement provides a more reliable 
determination of mean arterial pressure, but systolic and diastolic blood pressures are calculated 
rather than measured directly.326 Since our main goal was to investigate the change in the AgI 
caused by insulin in the same individuals at different time points, it is unlikely that use of the 
generalized transfer function influenced our results. The parallel decreases in aortic systolic blood 
pressure and the AgI supports this interpretation. It has also been previously shown that the 
changes in the AgI derived from radial measurements after GTN or norepinephrine administration 
correlate well with changes in the AgI measured without transfer function.250 
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The AgI measured from carotid artery with pulse wave analysis has been shown to independently 
predict cardiovascular mortality in patients with end-stage renal failure,219 providing the first 
evidence that increased arterial wave reflection is an independent predictor of cardiovascular 
disease. AgI measured from radial artery correlates with carotid artery intima-media thickness in 
diabetic and non-diabetic subjects,295 but it has not been shown to predict mortality. Pulse wave 
analysis as a method is relatively cheap, rapid and can be performed at an office visit. It is easy to 
use after a short training period and there is good inter- and intra operator reproducibility.82; 269 
Prospective studies are still needed to show whether the AgI predicts vascular end-points in 
patients groups other than end-stage renal failure.  
 
The exact mechanisms responsible for the effect of insulin on large arterial function and central 
haemodynamics remain unclear. Insulin dilates peripheral resistance vessels, in part, via the 
release of endothelium-derived NO.314 In resistance arteries, insulin-induced vasodilatation in vivo 
can be abolished by co-infusion of L-NMMA but not by other vasoconstrictors such as 
norepinephrine.415 Insulin has also been shown to potentiate acetylcholine but not sodium 
nitroprusside induced vasodilatation in human resistance arteries in vivo.341; 389 The fact that 
peripheral vasodilatation to insulin is blunted in subjects with endothelial dysfunction334 has lead a 
number of investigators propose endothelial dysfunction as a cause of insulin resistance, although 
this has been questioned.415 Endothelium-derived NO has recently been shown to regulate large 
arterial stiffness.185; 400 If the action of insulin on large arteries is mediated in part by NO then 
endothelial dysfunction rather than insulin resistance may cause the blunted effect of insulin on 
large artery mechanics. Indeed studies in patients with type 2 diabetes, a condition associated with 
insulin resistance and endothelial dysfunction, have demonstrated raised central pulse pressure 
compared to non-diabetic controls.53 
 
GTN also exhibits beneficial effects on arterial mechanics by reducing central aortic pressure 
without changes in heart rate or peripheral blood pressure.160 As with the haemodynamic effects of 
insulin, GTN exerts its action on central aortic augmentation at low doses whilst it is only at high 
doses that GTN produces arteriolar dilation and decreases peripheral vascular resistance.160 In the 
study I this action of GTN was confirmed and shown to closely correlate with that of insulin, 
independent of basal AgI. This implies that the previously described defect in the acute effect of 
insulin on central aortic augmentation391; 391; 392 is not specific to insulin and that vascular insulin 
resistance is associated with resistance to nitrates. This in vivo finding is consistent with that of 
effects of insulin and GTN previously described in platelets.21; 21; 359 Furthermore, the significant 
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correlation between the vascular effects of insulin and GTN suggests that at least some of the 
action of insulin on large arteries is mediated via NO. Although study I was not designed to assess 
mechanistic backgrounds to heterogeneity of vascular effects of GTN and insulin, one can 
hypothesize that large arteries may exhibit a generalized defect in vasodilator mechanisms in 
certain individuals. The close correlation between the vasodilator effects of GTN and insulin may 
also reflect insulin-mediated nitric oxide release causing vasodilatation specifically in large 
arteries. 
 
As in previous studies, 6 months of insulin therapy improved insulin-dependent whole body 
glucose disposal, despite inducing weight gain.144 Such an improvement could reflect correction of 
relative insulin deficiency413 and accompanying metabolic changes such as lowering of glucose 
and FFA concentrations.373 Weight gain in the present study was greater than would have been 
expected based on previous studies, where the average weight gain has been 2 kg for a 1 % unit 
decrease in HbA1C.230 In the present study weight gain was 3.75 kg for a 1 % unit decrease in 
HbA1C. The combination of insulin and glimepiride seemed to cause greater weight gain than 
expected in this group of type 2 diabetic patients, whose BMI averaged 30.8 kg/m2 before insulin 
therapy. Use of metformin instead of glimepiride might have prevented such excessive weight 
gain.408  
 
The novel finding in the present study was that the basal AgI decreased significantly by 6 months 
of insulin therapy. Given the multiple metabolic changes induced by insulin therapy, it is not 
possible to identify the factors responsible for this change with certainty. The changes in glucose 
and lipid metabolism could improve endothelial function and have antiatherogenic effects.373 
Increased bioavailability of NO due to decreases in oxidative stress caused by hyperglycemia 
could improve vascular function.350 Small LDL size is also a correlate of endothelial 
dysfunction.366 Insulin therapy increases LDL size,56 which also could improve vascular function. 
In cultured endothelial cells insulin increases NO production by increasing the expression and 
activity eNOS.193; 420 Insulin has been shown to enhance endothelial function measured as ACh 
induced vasodilatation both acutely and after long-term insulin treatment.373; 374; 389 Insulin 
treatment also decreases circulating vascular adhesion molecules such as E-selectin.304 FFAs cause 
vasodilatation and increase basal forearm blood flow when infused acutely, but impair ACh 
induced endothelium-dependent vasodilatation.83 Acute increases in insulin concentrations have 
been shown to reverse endothelial dysfunction induced be circulating FFAs218 and therefore the 
decrease in FFAs caused by insulin therapy might have contributed to the decrease in the AgI. 
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Insulin action on vascular tissue could also theoretically be improved by insulin treatment. Insulin 
therapy increased the basal insulin concentration 2.5-fold to 28 mU/l. We established in study I a 
dose-response curve for insulin action on the AgI and showed that acutely 30 mU/l of insulin is 
sufficient to significantly decrease the AgI. Thus, simply the increase in the basal insulin 
concentration may have decreased basal AgI. The acute decrease induced by insulin before and 
after insulin therapy remained unchanged. This does not, in view of the sensitivity of decreases in 
the AgI to small increments in serum insulin concentrations exclude the possibility that sensitivity 
of the insulin-induced decrease in the AgI was enhanced, because the insulin concentration 
achieved during the insulin infusion may have been too high to detect a change. 
 
Study I demonstrates that insulin at physiological concentrations decreases the AgI, which is 
associated with a fall in central systolic pressure in subjects in whom the amplitude of the reflected 
wave determines systolic pressure. Study II demonstrates that the ability of insulin to decrease 
aortic systolic pressure is blunted in type 2 diabetic patients. Our findings provide one potential 
link between insulin resistance and systolic hypertension. The data obviously do not exclude the 
possibility that insulin resistance affects blood pressure via other mechanisms such as via 
excessive activation of the sympathetic nervous system.18; 19 Study III shows that six-month insulin 
therapy might have beneficial effects on vascular function by decreasing the AgI. The effects of 
insulin therapy on vascular function is consistent with the results of the DIGAMI study,235 that 
showed that insulin therapy can decrease cardiovascular mortality in type 2 diabetes. If these 
results can be confirmed by other studies it might favour the use of insulin earlier in the course of 
type 2 diabetes.  
 
STUDY IV 
Study IV was undertaken to examine whether insulin resistance is associated with the degree of 
inhibition of platelet aggregation after in vivo ASA administration. We found that the ability of 
ASA to inhibit platelet aggregation induced by AA and ADP was significantly blunted in a group 
of obese insulin-resistant subjects compared to age- and gender matched normal-weight subjects. 
AA-induced aggregation was more strongly inhibited by ASA than ADP-induced aggregation. 
ADP at higher concentrations (2 and 3 µmol/l) overcame the inhibition of COX1 in the obese 
subjects, whose platelet aggregation returned to baseline. The difference between obese and non-
obese subjects could reflect the impact of ADP-induced release of AA. The obese may continue to 
activate thromboxane receptors and aggregate platelets in spite of ASA. Also the platelets of the 
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obese are known to have reduced levels of cAMP and cGMP, which may lower the threshold for 
activation.359; 388 
 
To study the interindividual variation in the platelet ASA responses, we chose to administer the 
lowest effective dose of ASA targeted to antithrombotic prophylaxis to maximize the likelihood of 
detecting interindividual differences.280; 376 The result might have been different if a larger dose or 
longer period of ASA use had been chosen. At doses smaller than 100 mg the effect of ASA is 
cumulative over a few days time.146; 277; 278 In patients with acute myocardial infarction it is 
recommended that a larger initial dose of ASA should be used to inhibit platelet function. In the 
Second International Study of Infarct Survival (ISIS-2) study 162.5 mg was proved beneficial.1; 279 
Normally maximal ASA concentration with soluble formulations of 50-1200 mg is reached within 
13-27 minutes.47 Maximal ASA concentrations measured in acute myocardial infarction with 100 
mg rapid release tablet were smaller and peak concentration was measured later (0.71 hours vs 
0.48 hours) than in control subjects. The difference resulted possibly from reduced flood blow to 
splachnic bed and delayed gastric emptying.47 In study IV, we took blood samples 1 hour after 
chewed ASA tablets. One hour should be enough time to reach maximal absorption in healthy 
obese or non-obese subjects, but the effect on platelet aggregation may well have been 
submaximal with a single 50 mg dose. We also only studied aggregation and not thromboxane 
production or closure times with platelet function analyser (PFA-100). Although optical 
aggregometry is the traditional and largely used method of studying platelet aggregation, the 
method is highly unphysiological and the conditions for platelet aggregation bear little 
resemblance to those in blood flow. Sample handling, preassay conditions and the timing of the 
preparation have to be standardized as far as possible, but there is still a large day-to-day and 
between operator variation.259 There is also no evidence that the effect of ASA on optical 
aggregation study would correlate with clinical events142 but there are results, which suggest that 
closure time with PFA-100 predicts cerebral and myocardial events.17; 131 Results from optical 
aggregometry and PFA-100 have however been shown to correlate.233 
 
The term ’ASA resistance’ has been used in several contexts to describe either individuals who 
experience vascular events despite using ASA,297 or who do not respond normally to ASA by 
some laboratory measure. These include the ability of ASA to prolong bleeding time174 and to 
inhibit aggregation responses to various agonists.134; 141; 142; 367 The causes of interindividual 
variation in ASA responsiveness are poorly understood and could involve in clinical trials factors 
such as non-compliance or drug-interactions.297 There is also some evidence that platelet responses 
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to ASA vary for other reasons. The antiplatelet effect of a fixed dose of ASA is known not to be 
constant in all subjects over time.142 In the study of Kawasaki et al, 8 healthy subjects were 
classified as non-responders or responders to ASA based on prolongation of their bleeding time. 
Platelets of 3 subjects classified as non-responders had increased sensitivity to collagen before 
ASA administration compared to the responders.174 This finding is reminiscent of that in the study 
IV, where the subjects who had a blunted response to a single dose of ASA also had increased 
sensitivity to ADP before ASA administration. In addition, we found that poor response to ASA 
was confined to obese and insulin resistant subjects suggesting that insulin resistance or obesity 
may be one cause of impaired antiplatelet effect of ASA. The observed differences cannot be due 
to differences in ASA drug levels between obese and lean subjects since platelets are inhibited in 
the portal circulation during drug absorption, thus the antiplatelet effect of aspirin is largely 
independent of systemic bioavailability. As a consequence, while very little drug is detected 
systemically, already 95% of platelet COX-1 is inhibited.283 
 
The meta-analysis of Antithrombotic Trialists’ Collaboration suggests that diabetic (including both 
type 1 and type 2 diabetic patients) might have smaller relative benefit from ASA use than non-
diabetic subjects.6 Primary Prevention Project also indicates that in diabetic subgroup the effect of 
ASA may not as good as in non-diabetic group.308 Unlike ASA, GP IIb/IIIa inhibitors seem to be 
more effective in diabetic than non-diabetic group.300 One might speculate that the increase in 
glycoprotein expression and the inability of ASA to inhibit platelet glycoprotein expression are of 
significance among the many defects described in diabetic platelets.  
 
Although many abnormalities in platelet function have been ascribed to ‘diabetes’, the control 
subjects have in many studies been younger and less obese than the patients with 
 diabetes.79; 157; 161; 188; 290; 317 These data raise the possibility that while hyperglycemia may be a 
cause of abnormal platelet function,405 other factors such as obesity or insulin-resistance associated 
with obesity could also have contributed to the various abnormalities ascribed to ‘diabetes’. Study 
IV where we found baseline ADP-induced platelet aggregation to correlate with the degree of 
insulin resistance in non-diabetic healthy subjects, suggests that body weight or insulin sensitivity 
indeed should be considered whenever diabetic and non-diabetic subjects are compared. 
Consistent with the importance of obesity or insulin resistance on platelet function, the 
antiaggregatory in vitro effects of both insulin and glyceryl trinitrate have been found to be 
impaired in obese healthy and type 2 diabetic subjects and preserved in lean type 2 diabetic 
patients and their weight-matched controls.21; 359 
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It is important to emphasize that abnormalities in platelet function tests in vitro and impaired 
platelet-inhibitory effect of ASA may not translate into an increased risk of cardiovascular events. 
However, the data suggest that future or ongoing trials examining the impact of ASA or other 
antiplatelet agents on vascular events or efficacy of ASA in patients with diabetes might want to 
include relative body weight or some measure of insulin resistance as a potential confounding 
variable. This would seem important since both obesity and other features of insulin resistance are 
associated with increased risk of coronary heart disease and stroke.288 Possibly, insulin-resistant 
obese subjects might benefit from ASA in combination with clopidogrel or therapies inhibiting 
platelet aggregation by blocking thromboxane-independent pathways or thromboxane receptors. 
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11 SUMMARY 
 
Insulin and GTN both decrease the AgI in a dose-dependent manner, although the time course of 
action for insulin is slower than that of GTN. In a group of apparently healthy middle-aged 
subjects the haemodynamic effects of insulin and GTN are closely correlated, independently of 
basal AgI. These data suggest that any variation in the action of insulin on large arteries in insulin-
resistant subjects is not specific to insulin and that individuals who respond poorly to insulin also 
do so to nitrates. 
 
Type 2 diabetic patients are resistant not only to the action of insulin to stimulate glucose uptake 
but also to its ability to decrease the AgI. The decrease in the AgI in the normal subjects was 
accompanied by a significant and rapid decrease in aortic systolic blood pressure. The ability of 
intravenous insulin to decrease the AgI and central systolic blood pressure is delayed in type 2 
diabetic patients when compared to age and weight matched normal subjects. 
 
Six months of basal insulin therapy improves insulin sensitivity in type 2 diabetic patient, in poor 
metabolic control with oral hypoglycemic agents, despite weight gain. Insulin therapy significantly 
decreases the AgI measured before insulin infusion and the AgI measured during hyperinsulinemia 
but does not alter the change in the AgI induced by insulin infusion. These data suggest that 
insulin therapy has beneficial effects on aortic wave reflection. 
 
The ability of ASA to inhibit platelet aggregation induced by AA and ADP is significantly blunted 
in a group of obese insulin-resistant subjects compared to age- and gender matched normal-weight 
subjects. In vivo insulin sensitivity is closely inversely correlated with aggregation responses 
induced by ADP before ASA administration, and to aggregation responses to both AA and ADP 
after oral ASA. 
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